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The increasing interest in the medical application of nanotechnology has heightened 
the need for synthesizing nanoparticles with well-defined dimensions and 
multifunctionalities. Studies on template synthesis demonstrate relatively reliable 
reproducibility of the nanostructures. Moreover, differential modification can be 
achieved with template synthesis method.  
Based on template synthesis method, magnetic nanotubes (MNT), silica nanotubes 
(SNT) loaded with superparamagnetic iron oxide nanoparticles (SPION), were 
successfully prepared. The magnetic properties of MNTs including saturation 
magnetization (Msat) and magnetic resonance (MR) relaxivities were investigated. 
Results revealed that Msat of MNTs is as high as 95 emu/gFe, which is on the highest 
side of reported value for magnetite nanoparticles. The MR study showed that MNTs 
enhanced proton MR relaxation considerably, especially transverse relaxation T2 (*). 
The transverse relaxivities (r2(*)) of MNTs are higher than that of Feridex, a FDA 
approved MR contrast agent, indicating that MNTs could potentially act as 
efficacious T2(*)-weighted MR contrast agents.  
MNTs were also studied as drug carriers to control the loading and release of 
Doxorubicin (Dox: a cancer drug model). The inner surfaces of MNTs were modified 
with C18- and pyridine-silane with various ratios. The results showed that Dox 
molecules held in the MNTs were stable at pH 7.2, and released at pH 4.5. With 
proper modification, MNTs can be used to control drug release profiles. The magnetic 
nanoparticles in MNTs helped in loading drug molecules due to barrier effect.  
Cytotoxicity and cellular uptake of SNTs with two different sizes and surface charges 
were investigated for two cell models, primary (non-malignant) and cancer cells. The 
nanotubes showed limited toxicity which was concentration-, surface charge-, and 
length- dependent. The internalization was confirmed with both confocal microscopy 
and TEM studies. Confocal microscopic images demonstrated that endocytosis was 
one of the main mechanisms for internalization of nanotubes.  
A novel method was developed in this thesis to improve multifunctionality of SNT as 
a drug delivery system by modifying the nanotubes segmentedly between the 
entrance and the remainder. Ideally, we can make a universal delivery vehicle with 
SNTs as the constitute structure which can be filled with therapeutic and imaging 
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Chapter 1: Introduction 
This chapter has been reproduced in part with permission from: Son, JS; Bai, X 
and Lee, SB, Inorganic hollow nanoparticles and nanotubes in nanomedicine. Part 
1: Drug/gene delivery applications. Drug Discovery Today 12(15-16): 650-656; 
Part 2: Imaging, diagnostic, and therapeutic applications. Drug Discovery Today 
12(15-16): 657-663 
 
The global drug delivery products and services market is projected to surpass $67 
billion in 2009. The nanotechnology-enabled drug delivery systems will generate 
over $1.7 billion ($US) in 2009 and over $4.8 billion in 2012 according to a newly 
released report from NanoMarkets, an industry consulting firm[1].  
1.1 Nanoparticles as drug carriers 
Why nano? For conventional therapy, the drug concentration in the blood rises 
when the drug is taken, then reaches a peak and goes down. A controlled drug 
delivery system is designed to achieve a prolonged therapeutic effect by releasing 
the drug continuously over an extended period of time[2], as shown in Figure 1.1. 
For some drugs, the peaks can cause terrible side effects, and in the valleys the 
drug is not effective[3]. The therapeutic index is used to define this property of a 
drug. It is expressed as a ratio between the toxic dose and the therapeutic dose[4]. 
Generally, it is measured by the lethal dose of a drug for 50% of the population 
(LD50) divided by the minimum effective dose for 50% of the population (ED50), 
that is, LD50/ED50. It is known that the side effects are mainly due to the non-
specificity of the chemotherapy, indicating that side effects can be reduced or 




most current anticancer drugs do not differentiate between cancerous and normal 
cells. The maximum allowable dose of the drug is thus limited to avoid toxicity. 
Additionally, rapid elimination and widespread distribution of the drug demand an 
administration in a large quantity and make the chemotherapy quite costly. 
Therefore, it is crucial to improve the drug efficacy and reduce the side effects by 
administering proper doses of chemotherapeutic drugs in a controlled and targeted 













 of an active drug 
 
Figure 1.1 Principle of drug controlled release 
(www.azom.com/Details.asp?ArticleID=745) 
 
Nanomedicine, a newly emerging discipline, is described as medical applications 
of nanotechnology to improve healthcare, particularly in cancer[2]. The 




physicochemical properties of nanoparticles. Basically, nanoparticles can protect 
the active agent from premature degradation, accomplish targeted delivery of 
large and different payloads, and can be multifunctional and versatile (Figure 1.2).  
 
Figure 1.2 Multifunctional nanoparticles[3] 
 
Tumor tissue is different from normal tissue in terms of the structure and behavior 
of the vasculature and lymphatic systems[5], as illustrated in Figure 1.3. The 
tumor vasculature, which is leaky, undergoes continuous angiogenesis in order to 
provide enough nutrients to the growing tumor. Additionally, the lymphatic 
capillary at the tumor site is very tight or missing, and can not function effectively 
as a drainage system. This results in the accumulation of nanoparticles in the 




enhanced permeability and retention (EPR) effect. EPR effect has been considered 
as a main mechanism for passive targeting of nanoparticles. Targeted drug 
delivery via the EPR effect is mostly useful for solid, nonmetastatic tumors. 
Studies on using liposomes with different mean size for passive targeting suggest 
that the threshold size for extravasation into tumors is ~400 nm, but other studies 
have shown that particle size less than 200 nm is more effective [6-8]. Moreover, 
a surface marker, antigen or receptor is generally over-expressed on tumor cells 
relative to normal cells. For example, growth factor receptors and proteins 
involved in cell-cell or cell-matrix interactions are usually up-regulated on the 
surface of tumor associated endothelial cells [9-11]. Nanoparticles with 
multivalent binding effects will have stronger binding affinity than monovalent 
binding of free drug molecule. This enhanced affinity can also be used to improve 
targeting [6].  
Goals of nanomedicine include identifying cancer in its earliest stages, visualizing 
development of the disease, delivering improved therapy to increase the 
effectiveness and reduce side effects of drugs, and capturing early signals of drug 
efficacy[13]. Paras Prasad, Ph.D., a professor of chemistry at the University of 
Buffalo, and Raoul Kopelman, Ph.D., a professor of chemistry, physics, and 
applied physics at the University of Michigan, have developed nanoparticles that 
can detect tiny tumors in living animals and at the same time deliver potent, light-
activated cell killers specifically to the tumor locations[13]. In fact, nanomedicine 




form of doxorubicin made by Ben Venue Laboratories for Johnson & Johnson, 
used in the treatment of a wide range of cancers, and Ferridex, a dextran coated 







Figure 1.3 Schematic illustration of the EPR effect principle. (a) normal tissue and 
(b) tumor tissue. Angiogenesis and enhanced vascular permeability of tumor 
capillaries and impaired or missing lymphatic clearance of nanoparticles result in 





In summary, nanomedicine has enormous potential to increase opportunities for 
prevention, diagnosis and treatment of cancer. Here, I will focus on the 
application of inorganic hollow nanoparticles for drug delivery and imaging. 
1.2 Targeted drug delivery systems 
Over a century ago, Paul Ehrlich envisioned the creation of "magic bullets," 
compounds that would have a specific attraction to disease-causing 
microorganisms and destroy them, while avoiding other organisms and having no 
harmful effects on the bodies of patients [14]. The concept of targeted drug 
delivery was then formed. 
Recently, nanotechnology has been rapidly emerging in biomedical and 
biotechnological applications, including drug/gene delivery carriers, disease 
diagnosis, and cancer therapy. In most applications, bio-nanomaterials such as 
liposomes and biodegradable polymers have played key roles in nanomedicine 
because they are considered to be safe in the human body [15, 16]. In contrast, the 
use of inorganic nanomaterials such as carbon nanotubes, metals, and metal oxide 
nanoparticles has been limited by safety issues in biomedical applications.  
Since recent cytotoxicity studies on carbon nanotubes (CNTs) have shown that 
biocompatibility of nanomaterial might be mainly determined by surface 
functionalization rather than by the size, the shape, and the material itself [17, 18], 
inorganic nanoparticles are attracting great interest in the field of nanomedicine. 
Inorganic nanomaterials have fundamental advantages over bioorganic 




functionalization [3, 19]. In addition, since inorganic nanomaterials permit a wide 
range of functionality arising from their unique optical, electrical and physical 
properties, they may provide a solution for many biological barriers that limit 
biomedical applications.  
Nanotubes, nanoshells and mesoporous nanoparticles are attractive vehicles for 
drug/gene delivery due to their hollow and porous structures and facile surface 
functionalization. The inner void can take up a large amount of drug and the open 
ends of pores serve as gates that can control the release of drug/gene. Furthermore, 
the hollow tubular nanoparticles can be differentially functionalized between the 
inner and outer surfaces, which can provide a platform of multifuntionalities into 
the nanoparticle through sequential and sectionalized surface modifications.  
1.2.1 Carbon nanotubes 
Although carbon nanotubes (CNTs) have attracted increasing attention as new 
vectors for the delivery of therapeutic molecules due to the ease of translocation 
across cell membranes and low toxicity [20-23], issues about the ultimate 
biocompatibility of CNTs have limited their use in biomedical applications [24-
26]. However, a recent study reported by Singh et al. revealed that water-soluble 
functionalized CNTs can be rapidly cleared from the systemic blood circulation 
through the renal excretion route [17]. Less than 1% of injected nanotubes were 
detected in all organs measured three hours after intravenous administration of 
nanotubes injected through the tail vein of a mouse. Functionalized CNTs have 




immunogenicity studies, peptide-CNT conjugates were recognized by antibodies 
as well as were free peptide. No immune response to CNTs was detected and gene 
expression efficiency offered by DNA-CNT was about 10 times higher than that 
of DNA alone [10].  
For the mechanism of cell membrane penetration, a spontaneous process, Bianca 
et al. proposed that CNTs behave like nanoneedles and pass through the cell 
membrane without causing cell death [28]. The reduced toxicity was thus due to 
the rapid internalization of CNTs into the cytoplasm of cells and hence reducing 
the possibility of disruption of the cell membrane structure. 
1.2.2 Nanocapsule and mesoporous nanospheres 
Mesoporous silica nanosphere  
Mesoporous silica nanoparticles are silica nanoparticles with an ordered pore 
structure. MCM-41, among this family, is the one that has been most extensively 
studied. MCM-41 type mesoporous silica nanospheres (MSN) have hexagonal 
arrays of cylindrical mesopores. Generally, the MSNs are synthesized by self-
assembly of a silica/surfactant mixture in which inorganic species simultaneously 
condense forming mesoscopically ordered composites [29, 30]. The average size 
of MSNs is 200.0 nm with a pore size of 2.3 nm. Based on this structure, drug 
carrier systems have been developed for gene transfection with high efficiency 
and low toxicity [31]. Flow cytometry analysis on cells 48 h post-transfection 
showed an efficiency of 35% with the gene delivery system. This efficiency is 




(15% efficiency), SuperFect (10%) and Metafectene (16%). Capped with 
chemically removable cadmium sulfide (CdS) nanoparticles, the nanosystem can 
be used for stimuli-responsive controlled release of drug molecules [32]. Giri et al. 
developed a superparamagnetic nanoparticle capped MSN system using disulfide 
bonds for stimuli-triggered release[33]. They proposed that the MSN system could 
be a promising nanodevice for site-selective, interactive sensory and controlled-
release drug delivery.  
Hollow carbonaceous capsules  
Sun and Li have recently prepared hollow carbonaceous capsules with reactive 
surface layers via hydrothermal methods with the anionic surfactant sodium 
dodecyl sulfate (SDS) and glucose as starting materials. The void size within the 
capsule and the shell thickness can be tuned by adjusting the amount of SDS and 
the hydrothermal parameters, such as time, temperature and glucose 
concentrations [34].  
Calcium phosphate nanoshells 
Calcium phosphate, the main component of the skeletons and teeth of vertebrate 
animals, is biocompatible and biodegradable. Solid calcium phosphate particles 
have been widely investigated for their applications in biotechnology. Roy et al. 
[35, 36] have synthesized calcium phosphate nanospheres with diameter around 
80 nm to encapsulate DNA for targeted gene delivery. The results from studies 
carried out both in vitro and in vivo show promising tranfection efficiency. The 
nanoshell form of calcium phosphate has been reported by Schmidt and Ostafin 




particles, are vesicular systems where the drug can be stored and protected from 
premature inactivation. 
1.2.3 Nanotubes prepared from template synthesis  
Although nanoparticles have been successfully used in most nanomaterial-
involved biomedical and biotechnological applications, spherical nanoparticles 
still need to be improved in terms of surface modification and environmental 
compatibility, especially when multifunctionality is required. Since a sphere has 
only one surface, every surface functionalization takes place on the same surface, 
which may lead to interference among various functional groups. In this regard, 
nanotubes (NTs) can offer attractive alternatives for some applications that require 
multifunctionalities.  
NTs have inner and outer surfaces, which can be functionalized differently 
depending on their roles (e.g. the inside with drugs or imaging agents, and the 
outside with targeting moieties and antifouling agents). The inner void of the NT, 
for example, can provide space to load a large amount of drugs and its open end 
can serve as a gate for drug uptake/release. Due to these unique attributes of NTs, 
compared with spherical nanoparticles, NTs are considered ideal nanovectors for 
nanomedicine [19].   
Of the various synthetic methods for nanotube production, template synthesis [38] 
provides the easiest way to control nanotube size and shape. This method offers a 
general approach for preparing nanomaterials that involves the synthesis or 




nanopore membrane or other solid surface [39]. Figure 1.4 shows an alumina 
template that has cylindrical nanopores with monodisperse diameters and lengths. 
Porous alumina templates can be obtained by a well-established electrochemical 
anodization method on aluminum plates. The dimensions of the pores can 
typically be adjusted from five to a few hundred nanometers in diameter and from 






Figure 1.4 Scanning electron microscopic images of alumina template 





Another virtue of template synthesis is that differential functionalization between 
the inner and outer surfaces of nanotubes is possible [42], as shown in Figure 1.5. 
The modification of the inner surfaces of NTs is performed when they are still 
embedded in the pores of the template. In this step, the outer surfaces of the NTs 
remain unmodified because the template protects them. After obtaining free-
standing nanotubes by removal of the template, the outer surfaces of the NTs can 
be exposed for functionalization. Differential functionalization can thus be 
achieved.  
 
Inner surface modification 
(after selective dissolution of template) Outer surface modification 
(when NT embedded in template) 
 
 
Figure 1.5 Scheme for differential functionalization of silica nanotubes 
 
Silica nanotubes 
Chen et al. [43] reported fluorescent silica nanotubes (SNTs) for gene delivery. 




membrane via a sol-gel process with tetraethyl orthosilicate (TEOS) as the 
precursor. The inside of the SNT was then modified with 3-aminopropyl silane 
(APTS) to generate a polycationic surface to hold CdSe/ZnS core-shell quantum 
dots (QDs) or DNA molecules through the electrostatic forces. Green fluorescent 
silica nanotubes (gfSNTs) were used for a cell membrane permeability study. 
Confocal microscopy revealed that the gfSNTs entered about 60-70% of the cells 
by endocytosis and were mostly localized in the cytoplasm. In cytotoxicity tests, 
approximately 80% of the cells were still alive after the treatment with gfSNT, 
indicating that silica nanotubes are not especially toxic under these experimental 
conditions.  
For the gene delivery experiment, the plasmid DNA was inserted into the 
nanotube to form a DNA/SNT complex. The cytoplasmic green fluorescent 
protein (GFP) expression complex was observed with DNA/SNT, but not with 
free DNA. Although the efficiency of SNT-mediated DNA transfection (ca. 10-
20%) is less than that of conventional calcium phosphate (ca. 60-70%), the 
advantage of this strategy is that cargo biomolecules carried by SNTs can be any 
biomolecules, such as RNA or proteins. 
Magnetic nanotubes 
Son et al. have reported magnetic nanotubes (MNTs), silica nanotubes embedded 
with magnetite nanoparticles [44]. The main advantage of the drug carrier having 
a magnetic property is that it allows for the use of a powerful imaging technique, 




of the drug carrier can be controlled by an external magnetic field, and hence 
directed to specific anatomical sites in vivo. The combination of attractive 
magnetic properties with a tubular structure makes the MNT an ideal candidate as 
a multifunctional nanomaterial for biomedical applications. For the synthesis of 
MNTs, silica nanotubes were first prepared by the surface sol-gel (SSG) method 
[45]. The resulting template embedded with silica nanotubes was dip-coated with 
a 4:1 mixture solution of 1 M FeCl3 and 2 M FeCl2, dried, and treated with 1 M 
NH4OH [46].  
The inner void of MNTs can be used to control the release of drug molecules into 
a solution. To achieve this result, the insides of the MNTs were differentially 
functionalized with aminopropyltriethoxysilane, APTS. 5-fluorouracil (5-FU), 4-
nitrophenol, and ibuprofen (Ibu) were tested as model drugs for the controlled 
release experiments[44]. As shown in Figure 1.6, depending on pKa values (Ibu, 
4.8; 4-nitrophenol, 7.2; 5-FU, 8.1), different release patterns were observed. For 
example, 10% of the ibuprofen was released in 1 hr and 80% was released after 24 
hrs, whereas more than 90% of the 5-FU and the 4-nitrophenol were released in 
1h. Son et al. proposed that the strength of ionic interactions between drug 
molecules and amine groups of the nanotube inner surface is a main factor for the 
drug release from the inside of the NT. This suggests that the drug release rate can 
be controlled by regulating the modification of the inner surfaces of NTs based on 







Figure 1.6 Releasing profiles of 5-Fu, 4-NO2-Ph and ibuprofen from MNTs in 
phosphate buffer solutions (pH 7.4) [44] 
 
Another type of MNTs, heterostructured MNTs, was produced through layer-by-
layer (LbL) deposition of polyelectrolytes and nanoparticles in the pores of a 
track-etched polycarbonate membrane[47]. These MNTs are composed of 
alternating multilayers of cationic poly(allylamine hydrochloride) and anionic 
poly(styrene sulfonate), and then a multilayer of magnetite nanoparticles (NPs). 
The content of magnetite NPs was calculated to be 20% of the total mass of the 
MNTs on the basis of the saturation magnetization. Large uptake of anionic 
molecules was observed when MNTs were treated with acid (pH < 2.5). Lee et al. 
proposed that the increased capacity arises from the protonation of free amine 
groups within the multilayers and a pH-sensitive swelling of the polyelectrolytes. 
For use as drug carriers, three anionic molecules (ibuprofen, acid red 8 and rose 




that molecular structure, particularly the size of the anionic molecules, played a 
key role in sustained drug release. In the case of bulky rose bengal, sustained 
release was observed, whereas small ibuprofen was immediately released.  
Nanotubes corked with nanoparticles 
Surface functionalization has been used for NTs to control drug release [19, 48]. 
However, this approach does not offer a full range of drug release control. An 
alternative payload-release strategy was explored by Martin and coworkers by 
corking nanotubes with a chemically labile cap [48]. Open ends of NTs 
functionalized with amino groups were spontaneously corked with anionic 
aldehyde-functionalized latex NPs via Schiff base linkage when the NTs were 
embedded in the alumina template. More than 80% of liberated NTs from the 
template remain corked, indicating that NP caps are not attached to the ends of 
NTs by electrostatic interactions but rather by covalent imine linkages (Figure 1.7). 
Schiff’s bases are known to be thermodynamically unstable in the presence of 
water, but they proposed that the metastable condition of the assembled structure 
is possible due to the multiple points of contact between the NTs and NPs. They 
suggested that if NTs could be loaded with a payload, such as drugs or genes, 
before corking the open ends with a chemically labile cap, these NTs could be 







Figure 1.7 SEM images of (a) template embedded and (b) liberated corked 
nanotest tubes. Scale bar: 500 nm [48] 
 
Another approach to cap NTs was achieved by our group with gold nanoparticles 
(NPs)[49], as shown schematically in Figure 1.8. In this method, negatively 
charged 2-nm Au NPs were selectively immobilized on the positively charged 
inside of a nanotube through attractive electrostatic interactions. Since the non-
functionalized outer surface bears partial negative charges and the repulsive forces 
produced by Au NPs occupying the open ends blocks further diffusion of Au NPs 
into the channel of the NTs, the Au NPs were localized at the open end of 
nanotubes and were found neither on the outer surfaces of NTs nor on the deep 
inner surface. Pre-trapped Au NPs can serve as a seed for a “seed-mediated gold 
growth” reaction to make caps at the open end of the NTs [50]. In this reaction, 
HAuCl4 was exclusively deposited onto the pre-trapped Au NPs after reduction 
with ascorbic acid. The capping procedure can be potentially adopted for a general 







Figure 1.8 Scheme for partial modification of silica nanotubes with gold 
nanoparticles and gold capping [50] 
 
In summary, the unique properties of a variety of inorganic materials such as 
mesoporous silica and CNTs make it possible to enhance, or even surpass, the 
capabilities of conventional delivery. The fundamental advantage of the use of 
hollow and porous inorganic nanomaterials in biomedicine lies in 
multifunctionality and well-controlled physicochemical properties. Together with 
the generic transporting ability of porous materials, useful properties in 
biomedical applications such as magnetism and NIR absorbance, can be easily 
integrated in a single unit. However, more research is needed before the hollow 
and porous inorganic nanomaterials are able to be used outside of laboratory. 
Although long-term safety studies have to be thoroughly examined, recent studies 
show that the characteristics being used for assessing inorganic material safety for 




Inorganic nanomaterials can be appropriate for biomedical use with proper surface 
treatments.  
1.3 Nanoparticles for molecular imaging 
Molecular imaging is an emerging field that aims to integrate patient-specific and 
disease-specific molecular information with traditional imaging techniques[51]. It 
differs from traditional imaging in that probes are used to image particular targets 
on the cellular level. The ability of nanoparticles to interact with complex 
biological functions can provide information about the fundamental mechanisms 
and signaling pathways involved in the progression of disease [52].  
Organic fluorophore-based detection techniques have been widely used as 
imaging and signal transduction tools for the detection of trace levels of analytes. 
The photostability of the fluorophores, however, limits their application in 
complex environments, such as living bio-systems where degradation or 
photobleaching can occur. The potential of nanoparticles with various sizes, 
shapes and materials as the carriers of fluorophores or imaging agents has been 
studied as a possible solution to this problem. 
Quantum dots (QDs) are one of the most intriguing fluorescent probes, due to 
their unique optical properties. QDs have high quantum yields, high molar 
extinction coefficients (~10 – 100 times than that of organic dyes) and broad 
absorption with narrow, symmetric photoluminescence spectra from UV to near 
infrared [53, 54]; however, the bioconjugation of QDs is somewhat challenging 




Hollow and mesoporous nanoparticles, such as nanotubes, nanoshells and hollow 
spheres can be loaded with a large amount of imaging molecules, which will 
considerably enhance signal and sensitivity. The detection of trace amounts of 
biomolecules, critical for early imaging and diagnosis of cancer, will be facilitated 
by nanoparticles that are concentrated with imaging molecules. Additionally, the 
photostability of doped imaging molecules is increased by the protective carriers. 
Compared with polymer nanoparticles, the advantages of silica nanoparticles lie in 
well-developed silane chemistry, easy preparation and biocompatibility [55, 56]. 
In addition to functioning as imaging agents, hollow and mesoporous 
nanoparticles with distinct inner and outer surfaces have potential as drug carriers. 
To be able to detect, treat and report the success of therapy with a single injection 
will eventually be a future and challenging medical application of nanotechnology. 
Here, I will review recent developments of using hollow and porous inorganic 
nanomaterials for sensing and imaging.  
1.3.1 Optical imaging probes 
A fundamental limitation of molecular imaging is the signal to background ratio 
caused by non-specific adhesion of bio-imaging agents to surfaces [57], making it 
difficult to identify a low intensity signal. A molecular imaging agent that emits 
light following a particular molecular event is ideal for in vivo tissue pathology. 
With well-developed silane chemistry, various surface modifications of silica 




based bio-imaging agents are promising in nanomedicine as bioimaging agents 
[58]. 
The two general synthetic approaches to prepare dye-doped silica nanoparticles 
are the Stober method and a microemulsion process. Ow et al. [55] have 
synthesized multifunctional silica-based fluorescent nanoparticles using the Stober 
method. The encapsulation process first involves covalent attachment of the dye 
molecules to an amine-containing silica precursor to form a dye-rich core, 
followed by co-condensation of silica precursor with sol-gel monomer to form a 
denser silica network around the core. This approach enables the incorporation of 
a variety of dye molecules into the silica nanoparticles. These nanoparticles are 
monodisperse with a diameter of 30 nm. The fluorescent silica nanoparticles are 
20 times brighter than the constituent dye. Ow et al. [55] proposed that the 
protection of the fluorophore from the solvent by the silica shell increases the 
photostability and, hence, contributes to the enhancement of brightness.  
For the microemulsion process, dye-doped silica nanoparticles are synthesized by 
hydrolyzing tetraethyl orthosilicate (TEOS) in a reverse micelle or water-in-oil 
microemulsion system. The dye molecules are encapsulated physically in the 
silica matrix. Zhao et al. [59] synthesized these nanoparticles for bioanalysis 
applications as labeling reagents. The dye molecule was linked to a dextran 
molecule before the reverse microemulsion process. In this way, the organic dye 
molecules become more water soluble, more easily entrapped inside silica pores 




large amount of dye molecules in each silica nanoparticle makes feasible ultra-
sensitive detection in bioanalysis.  
Nanoshells have a high scattering optical cross-section and thus can also work as 
contrast agents for photonics-based imaging modalities, such as reflectance 
confocal microscopy and optical coherence tomography. The scattering of light in 
the near infrared (NIR) spectral range can provide optical signals for cancer 
detection whereas biological tissue has low inherent scattering. Loo et al. [60] 
have designed immunotargeted nanoshells to simultaneously provide both 
scattering and absorption at specific frequencies in the NIR spectral region for 
dual imaging/therapy applications. They successfully detected and destroyed 
breast carcinoma cells that overexpress HER2 using the antibody-conjugated 
nanoshells. 
1.3.2 Magnetic resonance contrast agents 
Ultra-short single-walled carbon nanotubes (US-tubes) loaded with Gd3+n-ion 
clusters have been shown to have a T1 relaxivity 40 to 90 times larger than any 
Gd3+-based contrast agent (CA) in current clinical use. The observed enhancement 
of the relaxation rate was considered to be mainly related to the proton/water 
exchange rate, the rotational correlation time, and the relaxation rate of the Gd3+ 
electron spin[35]. 
Taylor et al. have developed Gd3+-containing mesoporous silica nanospheres as 




enhancement. The dose (2.1 μmol/kg) is much lower than what is typically 
required of currently used contrast agents (0.1-0.3 mmol/kg).  
Titirici et al. have reported a simple one-pot synthesis of hollow spheres of 
crystalline metal oxide via a hydrothermal approach [62]. Various metal salts were 
dissolved together with carbohydrates in water and then heated at 180°C in an 
autoclave. Hollow spheres of various metal oxides, such as Fe2O3, Ni2O3, Co3O4, 
CeO2, MgO, and CuO, can be obtained. Template-free syntheses of water soluble 
and amine-functionalized magnetic hollow nanospheres have been developed by 
Wang et al. [63]. The hollow nanospheres were prepared by dissolving 1,6-
hexadiamine and sodium acetate in FeCl3 6H2O in ethylene glycol. By controlling 
the amount of the ligand, 1,6-hexadiamine, nanospheres of 100 to 200 nm were 
obtained. In vivo magnetic resonance imaging experiments revealed magnetite 
solid nanoparticles were obtained with a higher concentration of 1,6-hexadiamine 
and a smaller amount of anhydrous sodium acetate. The saturation magnetizations 
of the hollow spheres with a diameter of 150 nm and the nanoparticles with 
tunable size from ~15 to ~50 nm were determined to be 71.2 and 41.3-59.8 emu/g 
at 25°C. In vivo magnetic resonance imaging in live mice was performed with 25 
nm amine-functionalized magnetic nanoparticles as a contrast agent while no 




1.4 Cellular uptake of nanoparticles 
1.4.1 Endocytosis 
Large polar molecules or nanoparticles cannot pass through the hydrophobic 
plasma membrane of cells. Cells use endocytosis to take up nanoparticles [64-66] 
by envelope of particles with plasma membrane. There are three major types of 
endocytosis: phagocytosis, pinocytosis, and receptor-mediated endocytosis. 
Pinocytosis (cell-drinking) is a process related with the uptake of solutes and 
single molecules such as proteins. Phagocytosis (cell-eating) is a process for cells 
to ingest large objects, such as bacteria or viruses or dead cells. For receptor-
mediated endocytosis- a more specific active event, cells have pits coated with the 
protein (e.g., clathrin) that initiate endocytosis when the target particles bind to the 
receptor proteins in the plasma membrane. The cytoplasmic membrane folds 
inward to form coated pits and buds to form cytoplasmic vesicles[67]. 
1.4.2 Size and shape effects on nanoparticle internalization 
Research has been carried out to study the size and shape effects of nanoparticles 
on cellular uptake. To be an effective drug carrier, the size of nanoparticles need 
to be controlled. It must be small enough to avoid rapid filtration by the spleen, 
which has a filament spacing of about 200 nm, it must be small enough to avoid 
Kupffer cell-lined sieve plates with 150-200 nm-sized fenestrae [52]. Chithrani et 
al. have studied the size dependence of gold nanoparticle uptake[68]. The results 




maximum uptake occurs for nanoparticles with size of 50 nm, as shown in Figure 
1.8. A mechanism has been proposed by the researchers from the same group to 
explain the uptake process[69]. This “wrapping time” mechanism involves factors 
like the ratio of adhesion and membrane stretching, the membrane’s bending 
energy and particle size. NPs with a size about 50 nm would have the fastest 
wrapping time, as also suggested by Gao et al.[66]. 
 
 
Figure 1.8 Cellular uptake of gold nanoparticles with different size [68] 
 
Carbon nanotubes (CNTs) have been demonstrated as an effective carrier for gene 
and anti-cancer drug delivery[27, 70]. However, the mechanism of the cellular 
uptake of CNTs is not clear. One of the key advantages of CNTs over other 
nanoparticle carriers has been considered to be the possibility of crossing 
biological barriers effectively [71]. Dennis Dishcer and colleagues have reported 




diameter, and 2 to 8 um in length) have a blood circulation time that is ten times 
greater than their spherical counterparts and have a high efficiency in deliver the 
anticancer drugs [72]. However, the study on cellular uptake of gold nanoparticles 
(NPs) of different shapes showed a lower uptake of rod-shaped gold NPs in 
comparison to spherical shaped NPs and the rates of uptake were lower with an 




Chapter 2: Synthesis of Magnetic Nanotubes 
This chapter has been reproduced in part with permission from Bai, X; Son, SJ; 
Zhang, SX; Liu, W; Jordan, EK; Frank, JA; Venkatesan, T; Lee, SB, Synthesis of 
superparamagnetic nanotubes as magnetic resonance imaging contrast agents and 
for cell labeling. Nanomedicine 3(2): 163-174. 
2.1 Introduction 
The protocols for synthesis of superparamagnetic iron oxide nanoparticles 
(SPIONs) can be classified as water-phase and non-hydrolytic high-temperature 
growth methods[73-75]. The water-phase based methods generally produce 
SPIONs with poor crystallinity and a polydisperse size distribution. On the 
contrary, the high-temperature growth methods have better control of the size 
distribution and magnetic properties, but encounter difficulties in water solubility 
and surface modification. Magnetic nanoparticles without effective surface 
coating have very limited practical applications because their suspensions are 
quite unstable. They tend to aggregate and precipitate out of solution and their 
magnetic properties vary. Various types of biocompatible SPIONs have been 
developed, such as liposomes, dendrimers, polymer-coated, and silica-coated iron 
oxide, etc.[73, 76]. 
Silica nanotubes (SNTs), with well-defined, robust and monodisperse structures, 
have attracted intensive attention recently for biotechnological studies[39, 77-82]. 
SNTs have several important merits in terms of multifunctionality due to their 
structural features [39, 48, 83]: namely, (i) an inner void for accommodating 




reactions and nonspecific adsorptions; (ii) an open end for controlling drug uptake 
and release; (iii) distinctive inner and outer surfaces that can be differentially 
functionalized for imaging and targeting moieties. Lee and coworkers have 
recently used these concepts to prepare MNTs, a silica nanotube (SNT)/SPION 
composite. Although they demonstrated proof-of-concept experiments on 
chemical separations, immunobinding, and controlled drug release [44, 84], the 
saturation magnetization (Msat) was low (2 emu/g), which limited these 
applications of these materials. 
In this chapter, a method is designed to synthesize MNTs in order to obtain high 
value of saturation magnetization, Msat. The method is based on a polyol method. 
The polyol method was originally reported for the synthesis of monodisperse 
metal and polymetal fine particles in the late 1980s with inorganic salts, such as 
nitrates, alcoholates, as precursors. Polyol was used as both a reducing agent and a 
solvent. Oxide nanoparticles prepared by the polyol method have been recently 
reported with high yield, narrow size distribution and good crystallinity [85-88]. 
Scheme 2.1 illustrates the route for the preparation of MNTs. 
 
















2.2 Materials and methods 
Silicon tetrachloride (SiCl4, 99.8%, Acros Organics), oxalic acid (dehydrate, 
Acros), o-phosphoric acid (85%, Fisher), chromic acid (10%, W/C, LabChem, 
Inc.), hexane (Fisher), ethanol (Pharmco-AAPER), methanol (Fisher), and 
perchloric acid (70%, Fisher) were used as supplied without further purification. 
Aluminum foils (99.99%) and ferric chloride hexahydrate (FeCl3·6H2O 97.0-
102.0%) was obtained from Alfa Aesar (Ward Hill, MA), while propylene glycol 
(J.T. Baker, Philipsburg, NJ) and sodium acetate (ACS reagent) were obtained 
from Fisher Scientific. Deionized (DI) water was obtained by a Milli-Q A10 
system and used for all the experiments. All the silane agents were obtained from 
Gelest, including EDTA-silane (n-(trimethoxysilylpropyl)ethylenediamine, 
triacetic acid, sodium salt, 45% in water), DETA ((3-





2.2.1 Template synthesis of silica nanotubes 
The home-made alumina templates were prepared with a two-step anodization of 
aluminum plates (99.99%, Alfa Aesar). The cell setup is illustrated in Figure 2.1. 
An aluminum plate functions as the anode and two pieces of stainless steel act as 
the cathode in an electrolyte. The cell temperature is controlled by a water pump 




Figure 2.1. Electrochemical cell setup with an aluminum plate as the anode, 
stainless steel plates as the cathode in an electrolyte. 
 
The aluminum plates were first degreased by sonicating for 10 min in acetone. 
The plate was then electropolished with perchloric acid solution (perchloric acid: 
ethanol v/v = 1:5) at 15 V, 5 °C for 5 min. The electropolishing step produces 
stress-free and relatively uniform metal surfaces compared to the surfaces 




at 40 V and 10 °C in 0.3 M oxalic acid solutions. The process is demonstrated in 
Figure 2.2. When aluminum is oxidized to alumina, the volume expands. This 
leads to compressive stresses in the oxide layer since the oxidation takes place at 
the entire metal/oxide interface. This stress can promote the formation of well-
defined self-ordered pore structure of aluminum anodic oxide (AAO) films[90, 
91]. The AAO layer tends to become more and more ordered with anodization 
time. The oxide film obtained from the first step anodization was etched off by a 
mixture composed of chromic acid (1.5 wt%) and phosphoric acid (6 wt%). Since 
the anodic film formation involves generally the conversion of a pre-existing film 
on the surface[89] , second anodization results in a layer of AAO with a more 
ordered pattern. The thickness of the final oxide film was controlled by the second 
anodization time. The final pore diameter was controlled by a pore-widening step 
















Figure 2.2 Preparation of AAO templates with a two-step anodization 
 
SNTs were synthesized by depositing a silica layer in the pores of the templates 
via a surface sol-gel method[92], as shown in Scheme 2.2. The basic reaction is 
hydrolysis of SiCl4 to form silica (silicon dioxide). Briefly, the template was 
dipped in SiCl4, and then rinsed with hexane, a mixture of hexane and methanol, 
and ethanol in sequence. The rinsing process with organic solvents from low to 
high polarity is to remove unbound SiCl4 molecules to have a layer of SiCl4 left 
on the template surfaces. The template was then dried with nitrogen gas, and 
immersed in water to finish the reaction. The wall thickness of the nanotubes 


































The silica layer on the top surface of the template was removed via either 
mechanical polishing using alumina powder with a particle size of 0.3 μm (MSI, 




etching, the silica coated AAO was placed in a plasma chamber (Technics Model 
PE-IIA) and the chamber pressure was pumped down to 90 mTorr. CHF3 gas was 
then flushed in until the pressure reached 100 mTorr. The power was set to 150 W 
and the etching time was 2 min. During the plasma etching, free fluorine was 
produced by electron impact in plasma, and reacted with SiO2 to form SiF4 in the 
gas phase, which was pumped away. Free-standing nanotubes were then released 
by dissolving the alumina template selectively in a 25% phosphoric acid solution. 
TEM images were taken with ZEISS EM10CA TEM microscope (Thornwood, 
NY) operating at 80 kV. 
Figure 2.3 shows the TEM images of SNTs with different polishing method. It can 
be seen that the nanotubes obtained with dry etching did not have the residue 
shown at the entrance of the nanotubes obtained with mechanical polishing. The 
particles at the entrance could be ground silica particles produced during 
mechanical polishing. 
 
   
a b
Figure 2.3 TEM images of silica nanotubes obtained with (a) mechanical 




2.2.2 Synthesis of superparamagnetic iron oxide nanoparticles in the silica 
nanotubes 
Ammar et al.[85] have reported the synthesis of CoFe2O4 nanoparticles with a 
high crystallinity via a polyol method. Based on this method, we used FeCl3·6H2O 
as the precursor for the synthesis of SPIONs. Specifically, the SPIONs were 
prepared under reflux in 25 ml of 1,2-propanediol for 2 h in a 100 ml round-
bottomed flask fitted with a condenser. Sodium acetate was used as the 
hydrolyzing agent. FeCl3·6H2O with concentrations ranging from 0.002 M to 0.01 
M was used, while the concentration of sodium acetate was kept at three times the 
Fe concentration. 500 μl water was added in the 25 ml polyol medium for 
hydrolysis reactions. For the synthesis of MNTs, silica-coated alumina templates 
were introduced into the reaction media. After the reflux processes, the silica 
coated alumina templates were rinsed in ethanol and water. After removal of the 
silica coating on the top surfaces with mechanical polishing, the templates were 
selectively dissolved with 0.1 M NaOH solution. The SPION-loaded nanotubes 
were subsequently rinsed with ethanol and collected via filtration, and dispersed in 
water. For comparison, the SPIONs formed in the bulk solutions were also 
collected.  
2.2.3 Characterization of superparamagnetic iron oxide nanoparticles and 
magnetic nanotubes 
The template and MNT dimensions were characterized by field emission scanning 




electron microscopy (TEM). High resolution TEM images were taken with JEM-
2100F Field Emission Transmission Electron Microscope operating at 200 kV 
with STEM (Scanning TEM) capability and Oxford Energy Dispersive X-Ray 
Spectrometry (EDS). The magnetic properties were characterized by using the 
Quantum Design (MPMS-XL) superconducting quantum interference (SQUID) 
magnetometer.  
2.2.4 Iron content measurement  
The iron content of the MNTs was assessed with NMR relaxometry [93, 94]. The 
T2 relaxation time was measured with a custom-designed relaxometer (Southwest 
Research Institute, San Antonio, TX) at 23 ˚C and 1 Tesla. The relaxation times 
were collected using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence with 
500 echoes and inter-echo times of 1, 3, and 5 ms. A calibration curve was 
obtained by measuring 1/T2 with ferric chloride solutions with known 
concentrations. The solution was prepared by mixing a 500 μl ferric chloride 
solution with known concentration with 500 μl concentrated hydrochloric acid 
(HCl). To measure the Fe concentration of a MNT solution, a 500 μl MNT 
solution was mixed with 500 μl of concentrated HCl to dissolve iron oxide to free 
ferric ion and the relaxation time was obtained under the same conditions as for 
the standard solutions. The number of MNTs in the solution was estimated based 
on the surface area of the relative template with a pore density of 1010/cm2. The 
iron content of a single MNT was thus determined as the average iron content of 





2.3.1 Superparamagnetic iron oxide nanoparticles synthesized in the bulk 
solutions 
Different concentrations of FeCl3 6H2O were used: 0.001, 0.005, 0.01 and 0.05M. 
The concentration of sodium acetate was kept at three times of the concentration 
of FeCl3 6H2O. 0.2 ml water was added in for the complete hydrolysis of the 
metal salt and compensated for the loss of water during the reflux processes. The 
TEM images of SPIONs formed with different precursor concentrations are shown 
in Figure 2.4. The SPIONs synthesized in bulk solution with 0.002 M iron 
precursor for 2 h reflux have a diameter of 5-10 nm, and 7-15 nm with 4 h reflux. 
Figure 2.5 shows the TEM images of SPIONs formed in bulk solutions with 









Figure 2.4 Transmission electron microscopy (TEM) images for the magnetite 
nanoparticles synthesized with different precursor concentrations: a) 0.05M, b) 







Figure 2.5 TEM images for superparamagnetic iron oxide nanoparticles (SPIONs) 
obtained with 2 hrs reflux (a) and 4 hrs reflux (b) in a 0.002 M iron precursor 
solution (scale bar: 50 nm)  
 
2.3.2 Electron microscopy studies of magnetic nanotubes 
The size of the SPIONs formed in the 2 μm-MNTs with the two-step reflux in 
0.002M iron precursor solutions was about 3-7 nm based on TEM images. The 
difference in nanoparticle size between SPIONs formed in bulk and the SPIONs 
formed within MNTs indicates that the nucleation and growth processes of 
nanoparticles in the nanotubes might be different from the process in the bulk. The 
SEM images of the MNTs with 2-step reflux in iron precursor solutions with a 
concentration of 0.002 M are shown in Figure 2.6. The main element components 
of the MNTs were detected with Energy-dispersive X-ray spectrum (EDS). As 
shown in Figure 2.7, there are Fe, Si, O, Cu and C peaks. Fe, Si, and O peaks 
represent the composition of magnetic nanotubes. Cu and C peaks come from the 







Figure 2.6 Scanning electron microscopy (SEM) images of the top view (a) and 
side-view (b) of 2 μm-magnetic nanotubes (MNTs, length: 2 μm, diameter: 70 nm) 
embedded in a AAO template. 
 
 
Figure 2.7 Energy-dispersive X-ray spectrum (EDS) of magnetic nanotubes. Fe, Si, 
and O peaks represent the composition of magnetic nanotubes. Cu and C peaks 
come from the specimen grid and the Formvar carbon supporting film. 
 
The high resolution transmission electron microscopic (HR-TEM) image for 
MNTs was shown in Figure 2.8. The highlighted lattices have a d-spacing of 0.25 




the (3 1 1) lattice planes of magnetite [95]. However, the d-spacing values 
obtained from the diffraction pattern for maghemite (γ-Fe2O3) [96] are quite close 
to the values for magnetite (Fe3O4). It is hard to distinguish magnetite from 
maghemite just based on diffraction patterns. It is well known that the saturation 
magnetization (Msat) of magnetite is much higher than the Msat of maghemite [96]. 
The Msat of our magnetic nanoparticles is on the highest side of reported values for 
magnetite nanoparticles by other groups [97]. This further provides evidence for 










2.3.3 Iron content determination of magnetic nanotubes 
The iron content of MNTs was determined with NMR relaxometry. The 
calibration curve is shown in Figure 2.9. The iron content of 2 μm-MNTs was 
measured to be 0.714 ± 0.187 fg/MNT after the first reflux in 0.002 M iron 
precursor solution, and increased to 1.367 ± 0.473 fg/MNT after the second reflux. 
The Fe content of 500 nm-MNTs was 2.013 ± 0.651 fg/MNT with a 3-step reflux. 
















Figure 2.9 Calibration curve for relaxation rate (1/T2, s-1) as a function of iron 






The effect of surface modification was also studied. The iron content of the MNTs 
with different surface modifications was listed in Table 2.1. No significant 
difference was detected according to an F-test. 
 
Table 2.1 The iron content of MNTs with different inner surface modifications 
Iron content  (fg/NT) 
Modification of NT 
One-step reflux Two-step reflux 
bare 0.714±0.187 1.367±0.473 
PEG- 0.713±0.360 1.410±0.644 
DETA- 0.534±0.276 1.294±0.757 
EDTA- 0.610±0.158 1.497±0.371 
 
2.3.4 Magnetization of superparamagnetic iron oxide nanoparticles and 
magnetic nanotubes 
Figure 2.10 shows the distribution of SPIONs in ethanol with and without an 
external magnetic field. The magnetic-field (H) dependence of magnetization (M) 
taken at 300 K was shown in Figure 2.11. Neither the SPIONs nor the MNTs 
exhibited hysteresis, which is consistent with the superparamagnetic properties of 
iron oxide crystals. According to the SQUID results, the saturation magnetization 
(Msat) of the synthesized SPIONs was as high as 98 emu/gFe. This value is greater 
than the reported Msat values for dextran coated SPION ferumoxides (Feridex IV 
TM, 68 emu/gFe [98]) that is used clinically as a MR contrast agent. The Msat of 




mass of MNTs, which is fifteen times greater than the Msat of the previously 
reported magnetic nanotubes formed at room temperature (i.e., 2 emu/gMNT) [44]. 
This increase in Msat results from the increased crystallinity of nanoparticles 
formed at the high temperature employed with the solvothermal method [99, 100]. 
The HR-TEM images shows that the SPIONs formed in the nanotubes and in bulk 
solutions are crystalline (Figure 2.8).The slight decrease of the Msat of MNTs from 
that of SPIONs formed in the bulk demonstrated that the MNTs retained the 


































Figure 2.11 Magnetization (M) - magnetic field (H) relations (T = 300 K) of 2 
μm-magnetic nanotubes (MNTs) synthesized by a two-step 2 hrs reflux in 0.002 
M iron precursor solutions, and of superparamagnetic iron oxide nanoparticles 
(SPIONs) synthesized by a 4 hrs reflux in a 0.002 M iron precursor solution 
 
The temperature dependence of zero field cooled magnetization (ZFCM) and field 
cooled magnetization (FCM) was measured at H = 50 Oe (Figure 2.12). At high 
temperatures, both the ZFCM and FCM increase during cooling and these two 
magnetization-temperature (M-T) curves overlap with each other. Below certain 
temperature, the ZFCM decreases during cooling and gives rise to a cusp in the 
ZFCM-T curve, while the FCM continues to increase. This thermomagnetic 
behavior is a typical characteristic of the superparamagnetic nanoparticle system. 
The temperature at which the ZFCM cusp is located is the so-called blocking 
temperature (TB), which is related to the anisotropy energy ( ) of the magnetic 
particles. According to the relation of
B αE




the larger the size of the particles can be, where Keff is the effective magnetic 
anisotropy energy per unit volume and V is the average volume of the magnetic 
nanocrystal; kB is the Boltzman constant. Based on the blocking temperatures 
obtained, the average size of iron oxide crystals formed in 0.002 M precursor 
solutions with 4 hrs reflux (TB = 250 K) is larger than that of the particles formed 
in nanotubes with 0.002 M precursor solutions with 4 hrs reflux in total (T
B
BB = 91 
K), which is consistent with the TEM studies. In addition to the intrinsic 
contributions, such as shape, magnetocrystalline, or stress anisotropies, particle 
interactions can modify the energy barrier [102]. The difference in the magnetic 
dipolar interaction can also contribute to the difference in TB [101]. Generally, a 
flatter low-temperature FCM-T curve reflects stronger dipole-dipole interactions, 
so the nanoparticles formed in the bulk should have stronger dipole-dipole 
interactions than the MNTs. The SPIONs are present as clusters inside discrete 
SNTs. This separation by the nonmagnetic silica layer results in weak dipole-
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Figure 2.12 Field cooled (FC) and zero field cooled (ZFC) magnetization as a 
function of temperature for superparamagnetic iron oxide nanoparticles (SPIONs) 
obtained with 4 hrs reflux in 0.002 M iron precursor solutions (a), and 2 μm-
magnetic nanotubes (MNTs) obtained from two-step reflux with the same iron 






2.4.1 Polyol method 
Fe3O4 was produced in the solvothermal system by modified reduction reactions 
between FeCl3 and propane diol. Polyol has been used for preparing metal oxide 
nanoparticles functioning as a solvent, a reducing agent and a surfactant. The 
structure of this molecule is ideal for forming chelated complexes with metals 
when the molecules are deprotonated. Caruntu et al. have proposed the scheme for 
the complex formation and hydrolysis in diethylene glycol [86, 103]. Similarly, 




Scheme 2.3 Formation of magnetite in propane diol: (a) complexation, (b) 
hydrolysis, (c) condensation 
(a) 



























































2.4.2 Formation of superparamagnetic iron oxide nanoparticles  
At high temperatures with constant bubbling during the reflux process, the 
nucleation and growth processes are more controlled by thermodynamics, that is, 




kinetics[104]. Nucleation starts with a supersaturated solution. The degree of 
supersaturation can be expressed by  
eqCCS /=      Equation 2.1 
where C and Ceq are the solute concentrations at saturation and at equilibrium, 
respectively.  
Nucleation starts with a supersaturated solution. The degree of supersaturation 
increases with the precursor concentration, resulting in a lower activation energy 
for cluster formation, and thus a higher nucleation rates [105].  
According to the results of the TEM studies, the magnetic nanoparticles formed in 
bulk solution with a reflux of 2 hrs have a diameter of 5-7 nm; with 4 hurs reflux 
the diameter is 7-15 nm. The size difference between the SPIONs formed in the 
bulk and those formed in the nanotubes indicates that the nucleation and growth 
processes in the nanotubes might be different from the processes in the bulk. A 
higher viscosity and a lower dielectric constant have been observed in confined 
nanospaces [106-108]. This difference between nanopores and bulk may result in 
the retardation of nanoparticle growth in the pores compared to the bulk. Magnetic 
particles formed during the first reflux process may catalyze the growth of 
SPIONs in the nanopores during the subsequent refluxes. This can explain 
successful loading of magnetic nanoparticles with two-step reflux. 
2.5 Conclusions 
In this chapter, MNTs were prepared with considerably high saturation 




important for actual applications like MRI contrast agent, magnetic separation of 
drug molecules or cells, imaging-monitored drug delivery. The feasibility and 
efficiency of these applications are highly reliant on this parameter. The synthesis 
method introduced in this work is quite simple and does not require laborious 
washing and purification steps. 
The structure of MNTs integrates the characteristics of SNTs, such as facile 
chemistry, mechanical robustness, biocompatibility, and well-controlled 
dimensions, with the high saturation magnetization of SPIONs, making the MNTs 





Chapter 3: Magnetic Nanotubes as Magnetic Resonance 
Contrast Agents 
This chapter has been reproduced in part with permission from Bai, X; Son, SJ; 
Zhang, SX; Liu, W; Jordan, EK; Frank, JA; Venkatesan, T; Lee, SB, Synthesis of 
superparamagnetic nanotubes as magnetic resonance imaging contrast agents and 
for cell labeling. Nanomedicine 3(2): 163-174. 
3.1 Introduction 
Magnetic resonance imaging (MRI) has been used to produce high-resolution 
three-dimensional images of the inside of the human body primarily for medical 
purposes[109]. MRI is based on the principles of nuclear magnetic resonance 
(NMR). Differential contrast depends on endogenous differences in water content 
and relaxation times of the tissue of interest. Contrast agents such as gadolinium 
chelates, are used to increase the specificity of MRI. Such agents have been 
successfully used for the imaging of blood perfusion and vascular permeability 
[110]. However, the sensitivity of MRI is low and high local concentrations of the 
contrast agent are required to generate detectable MR contrast. The contrast agents 
should, therefore, be characterized by high relaxivity[111]. 
3.2 Basics of magnetic resonance spectroscopy 
3.2.1 Physics of magnetic resonance 
Protons are charged particles and possess a characteristic dipolar magnetic 
moment around their axis. In the absence of an applied magnetic field, the 




field B0 is applied in a direction, the z component of the individual magnetic 
moments of each proton will align either parallel or anti-parallel to the applied 
field. The parallel orientation is the lower energy state and the anti-parallel one is 
at the high energy state. The ratio of the populations of protons at these two 
energy states can be estimated with Boltzmann’s equation (Equation 3.1). 
)/exp(/ kTENN hl Δ=    Equation 3.1 
where Nl is the number of protons in the lower energy state and Nh is the number 
of protons in the higher energy state. T is the absolute temperature (K) and kB is 
Boltzmann’s constant (1.3181 x 10 -23 JK-1). ΔE is the energy difference between 
the two energy states, which is proportional to the applied field strength. At 
equilibrium, the net magnetization vector lies along the direction of the applied 
magnetic field B0 and is called the equilibrium magnetization M0. The 













There is a simple linear relationship between the magnetic field experienced by 
the protons and the resulting angular frequency of precession, ω0, of the 
magnetization, as described by the Bloch equation (Equation 3.2). 
00 Bγω = ,     Equation 3.2 
where γ is the gyromagnetic ratio which is unique for each nucleus possessing a 
spin,  and ω0 is the Larmor frequency associated with the spin energy transitions 
(ΔE) induced by the magnetic field.  
The net magnetization vector Mz, the magnitude of M0 in the z-direction, is small 
compared to the applied field. Mz can absorb energy from radio frequency (RF) 
radiation, such as a RF 90° pulse. When the RF source is removed, the protons 
relax or return to a state of equilibrium and emit energy to the surrounding nuclei, 
as shown in Figure 3.2. This is T1 relaxation or “spin-lattice” relaxation. T1 is the 
time for the magnetization to return to 1/e of its original magnitude (M0). The 



























−−=     Equation 3.3 
 
The net magnetization is placed along the –z direction when a RF 180° pulse is 




























−−=     Equation 3.4 
 
T2 relaxation or “spin-spin” relaxation occurs when spins at the high and low 
energy states exchange energy but do not loose energy to the surrounding lattice. 




due to a loss of phase coherence, called dephasing, as shown in Figure 3.4. The 
behavior of the Mz is then described by Equation 3.5. Two factors contribute to 
the dephasing. One is molecular interactions, which leads to a pure T2 relaxation. 
The other is variation in B0, which leads to an inhomogeneous T2 effect (T2inhomo). 
The time constant for the decay caused by the combination of these two factors is 




















−=      Equation 3.5 
oinTTT hom22
*
2 /1/1/1 +=     Equation 3.6 
 
3.2.2 Measurement of relaxation times 
Free induction decay (FID) is a form of magnetic resonance signal from the decay 











The T1 values can be measured using the sequence defined as 
nDxx TFIDTR ])(9090[
00 −−−  
Where 90°x is the 90° RF pulse along x-axis. TR is the repetition time, the time 
between the 90° pulses. 90°x(FID) is the measurement of MR signal of the 
recovered Mz during the TR time. TD is a delay time and n is the repetition times 
of the sequence. In this sequence, a 90° RF pulse is applied to rotate Mz to the xy-
plane. A second 90° RF pulse is applied to rotate the recovered Mz, the relaxed 




generally 3 to 5 times of T1. Mz will be completely recovered or close to M0 after 
TD. In each measurement the TR values are changed to generate a plot of signal 
intensity versus time (Equation 3.7).  
 
)1)(0()( 1/TTRzz eMTRM
−−= ,   Equation 3.7 
 
where Mz(TR) is the amplitude of the magnetization at TR, Mz(0) is the amplitude 
of the magnetization at time zero. T1 can also be determined with inversion 
recovery sequence, such as Philips Look-Locker sequence. The sequence is 
defined as 
nDxx TFID ])(90180[
00 −−−τ , 
where τ is the time between the 180° and 90° pulses. In this sequence, a 180° RF 




ττ −−=    Equation 3.8 
 
Transverse relaxation, T2
Spin-echo sequences are used to measure T2 values or for T2-weighted imaging by 










A RF 90° pulse is applied to rotate the magnetization to the xy-plane, Mxy. A RF 
180° pulse along the y-axis is then applied after one half of an echo time (TE) to 
refocus the spins that have dephased due to the inhomogeneities of the magnetic 
field. If the filed inhomogeneity is present for the first 1/2 TE delay, the same 
inhomogeneity is present for the second 1/2 TE after the 180° pulse and will 
influence the precession in the same manner. The effect of inhomogeneities of the 
magnetic field on the dephasing of Mxy can thus be cancelled out at the center of 
the echo where the spins are back in phase and the value of the echo reflects the 
T2 effects on the dephasing of the spins. The 180° pulse is often referred to as the 
refocusing pulse. The dephasing that occurs after the RF 90° pulse and on either 
side of the echo center is due to T2* effects. The echo time (TE) is the time 
between the RF 90° pulse and the formation of the echo. The repetition time (TR) 
is the time between the successive RF 90° pulses. The process is repeated n times 
to produce an echo train. The sequence is called a Carr-Purcell-Meiboom-Gill 
















−=    Equation 3.9 
 
T2* relaxation 
As mentioned before, T2* relaxation is caused by both the T2 relaxation and the 
dephasing by magnetic field inhomogeneities (Equation 3.6). T2* weighted MRI is 
commonly used in the presence of superparamagnetic nanoparticles as contrast 
agents in tissues. The gradient recalled echo (GRE) sequence is used for T2* 
weighted MRI. A RF pulse is used to rotate the magnetization by an angle 
typically of between 10° and 90°. Then, a gradient is used to rephrase the spins in 
the GRE sequence. The GRE sequence is intrinsically more sensitive to magnetic 
field inhomogeneities because of the use of the refocusing gradient. Comparing to 
the spin echo sequence, GRE uses a small flip angle to rotate the magnetization 
and a gradient instead of a 180° RF pulse to refocus magnetization vectors. This 
gives the sequence a time advantage over the T1 and T2 weighted imaging. It is 
widely used for fast scan images. T2* can be calculated from the exponential 










where SI(TE1) and SI(TE2) are the measured signal intensities at the first echo 
time (TE1) and the second echo time (TE2), respectively. ΔTE=TE2-TE1. The 
signal intensity (SI) is measured from a region of interest (ROI), determined from 
the MR image. It can also be determined directly from the line width of the proton 






Figure 3.5 T2* decay 
 
3.3 Magnetic resonance  contrast agents  
The MRI contrast is due to the response of protons to an external magnetic field. 
The relaxation of the protons is dependent upon the local environment, such as 
temperature and viscosity. Different tissue will relax at different rates. MRI 
contrast is determined by the difference in proton relaxation rates and proton 




agents are required to enhance the contrast by increasing proton relaxation rates. 
Generally, there is a linear relationship between the relaxation rate and the 
















Figure 3.6 T1 and T2 contrast 
 





where R1 or 2 is the relaxation rate in the present of contrast agent, r1 or 2 is the 
relaxivity of the contrast agent with a unit of s-1mM-1, C is the concentration of 
contrast agent, R0,1 or 2 is the relaxation rate of the sample without contrast agent. 
MRI contrast agents can be classified as positive contrast agents and negative 
contrast agents according to the increase or decrease of signal intensity in the 
presence of the agent. All contrast agents will enhance both T1 relaxation and T2 
relaxation. Whether the signal intensity is increased or decreased is dependent 
upon which effect predominates. The positive contrast agents can increase signal 
intensity on T1 weighted images by decreasing T1 more significantly than T2. 
They are typically paramagnetic agents that produce only weak local magnetic 
fields and therefore weak enhancement on T2*. These agents are generally small 
molecular weight compounds containing elements that have unpaired electron 
spins in their outer shells, such as gadolinium, manganese and dysprosium. They 
are chemically linked to carrier molecules since gadolinium and dysprosium free 
ions are quite toxic. These agents can be eliminated without any significant bio-
transformation in the body. Negative contrast agents are mostly particulate 
aggregates composed of a magnetic core, usually magnetite (Fe3O4) or maghemite 
(γ-Fe2O3), and a shell of polymer, dextran, polyethyleneglycol. 
Superparamagnetic iron oxide (SPIO) and ultrasmall iron oxide particles (USIO) 
are the two main types of negative contrast agents. These agents produce 
predominantly spin-spin relaxation effects. SPIO refers to particles with 




50 nm. USIO particles are made up of single crystalline iron oxide cores with a 
mean hydrated particle diameter less than 50 nm.  
3.4 Magnetic nanotubes as magnetic resonance contrast agents  
Superparamagnetic iron oxide nanoparticles (SPIONs) have been recognized as 
promising and powerful candidates for applications in medical and 
biotechnological fields, such as magnetic resonance imaging (MRI), cellular 
therapy, tissue repair, targeted drug delivery, etc.[73, 76, 112-116]. There is an 
increasing interest in MRI to monitor in vivo temporal and spatial migration 
behavior of the transplanted cells labeled with SPIONs [47, 117-120]. MRI is a 
noninvasive in vivo molecular imaging technique that provides a way to assess 
anatomy and function of tissues. However, one drawback of MRI is the low 
sensitivity and need for micromolar concentration of contrast agents in tissues 
[121]. The addition of MRI contrast agents increases the sensitivity to detect 
tumors at a very early stage, that would be otherwise undetectable with 
conventional imaging protocols [76].  
An ideal MR contrast agent should have a high magnetic moment, high colloidal 
stability, biocompatibility, long circulation time, and efficient surface 
functionality [73]. The high-performance magnetic nanoparticles depend highly 
on their physico-chemical properties, such as size, surface modification, and 
crystallinity, which are closely related with their synthetic methods. Dextran-
coated SPIONs have been used as MRI contrast agents to label cells ex vivo [119]. 




reticuloendothelial cells in the liver with a short half-life time in blood. The rapid 
biodegradation and clearance make it hard for long-term monitoring of the 
migration of these labeled cells in a biological system. Interestingly, it has been 
reported that the cylindrical shape of nanoparticles is able to sustain a drug 
delivery with a longer half-life time compared to nanospheres [72]. Spearing 
effect of nanotubes resulting in high efficiency in drug-delivery has been 
demonstrated [28]. 
Considering the unique characteristics of MNTs, as described in Chapter 2, the 
relaxivities of the MNTs prepared with polyol method were studied in this chapter. 
The results suggest that the MNT with a unique physical structure and high MR 
relaxivities make it suitable for use as a MRI contrast agent. 
3.5 Methods 
MNTs were embedded homogenously in phantoms (a 2% agarose gel). T1 and T2 
relaxivities were measured on a clinical 3T MR scanner (Acheiva, Philips Medical 
System, Best, The Netherlands) using a dedicated 7 cm rat solenoid receive only 
RF-coil (Philips Research Laboratories, Hamburg, Germany). A T1 relaxation map 
was acquired with a Look-locker sequence with 40 phases, echo time TE = 7 ms, 
repetition time TR = 5000 ms, flip angle = 10°. A T2 map was acquired with a 
multi spin echo sequence with 11 echoes, TE = 7.2 ms, TR = 1000 ms. A T2* map 
was acquired with a multiple gradient echo sequence with 15 echoes: TR = 1000 
ms, flip angle = 30°, TE of the first echo = 4.8 ms and inter echo step = 3.4 ms. 




192 × 192, reconstructed matrix = 256 × 256, slice thickness = 1 mm, number of 
excitations = 1. T1, T2 and T2* were calculated by mono-exponential fitting with  
custom-designed IDL software. The reported relaxation time was measured as the 
average over a regional of interest. The iron content of each sample was 
determined with a custom-designed relaxometer (Southwest Research Institute, 
San Antonio, TX) at 23 ˚C and 1 Tesla, as described in Chapter 2.  
3.6 Results and discussions 
Superparamagnetic nanoparticles generate contrast by shortening the NMR 
relaxation times. The efficacy of a MR contrast agent is commonly evaluated in 
terms of its relaxivities (r1 or r2), a measure of how much the proton relaxation rate 
is increased with the concentration of contrast agent. r1 and r2 are defined as the T1 
(spin-lattice) relaxivity and T2 (spin-spin) relaxivity, respectively. They are 
determined from the linear relationship between the relaxation rates (R1 or 2 = 1/T1 
or 2) and the concentration of the contrast agent (C), that is,  
(where,  is the relaxation rates in the absence of contrast agent). The 
relationships between the relaxation rates and the concentration of the MNTs are 






1 and T2 (*) relaxivities of the 500 
nm- and 2 μm-MNTs along with the FDA approved MRI contrast agent 
ferumoxides (Feridex IV; Berlex Laboratories, Wayne, NJ). The r2 to r1 ratios for 
the 500 nm-MNTs (r2/r1 = 175) and 2 μm-MNTs (r2/r1 = 134) are greater than the 
ratio of the ferumoxides (r2/r1 = 35) measured under the same conditions. This 




been reported by Martina et al. [122] and Berret et al. [123]. T2* weighted MRI is 
commonly used to detect the presence of SPION in tissues. The variation of the 
magnetic field in the presence of MNTs results in local magnetic susceptibility 
inhomogeneities and causes an increased loss of phase coherence of proton spins. 
This effect leads to an increase of T2* relaxation compared to surrounding 
environment and hypointense regions on T2* weighted MRI. MNTs have an r2* 
(628 mM-1s-1 for 500 nm MNTs, and 946 mM-1s-1 for 2 μm MNTs) greater than 
that for ferumoxides (r2* = 344). The results indicate that the clustering of 
magnetic nanoparticles in discrete nanotubes enhanced the r2, the ratio r2/r1 and the 
ratio of r2(*)/r1, which increases the MNTs utility as a T2 and T2* contrast agent 
[122, 123]. Figure 3.8 shows the T2- and T2*-weighted images of the phantom 
with a series of MNT concentrations obtained at 3 Tesla.  
 
Table 3.1 Relaxivities r1, r2 and r2* of ferumoxide and magnetic nanotubes (MNTs) 




r1 (mM-1s-1) r2 (mM-1s-1) r2* (mM-1s-1) r2/r1
ferumoxide - 6.5 ± 0.6 226 ±27 344 ±13 35 
500 nm-MNT 2.013 ± 0.651 1.6 ± 0.3 264 ± 56 628 ± 90 175 






























































Figure 3.7 Relaxation rates as a function of iron concentration (mM): (a) T1 
relaxation rates (1/T1, s-1), (b) T2 relaxation rates (1/T2, s-1), and (c) T2* relaxation 





T2- weighted images 
T2* - weighted images 
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Figure 3.8 T2- and T2*- weighted images for phantoms dispersed with (a) 500 nm-
magnetic nanotubes (MNTs) with concentration of 0, 2.4, 4.7, 9.5 and 19 pM (Fe 
concentration of 0, 0.085, 0.170, 0.213 and 0.426 mM), respectively, and with (b) 
2 μm-MNTs with concentration of 0, 3.3, 6.5, 13 and 26 pM (Fe concentration of 
0, 0.062, 0.124, 0.248, and 0.495 mM), respectively.  
 
3.7 Conclusions 
In this work, I demonstrated that MNTs enhanced proton magnetic resonance 
relaxation rates, especially r2 (*), that are comparable with those of commercially 
available MR contrast agents. The r2/r1 ratio of MNTs is greater than ferumoxides 
and would indicate that the presence of MNTs could potentially lead to increased 
changes in contrast enhancement as compared to clinically approved T2(*)-




Chapter 4: Loading and Release of Doxorubicin with 
Magnetic Nanotubes 
4.1 Introduction 
It is well documented that endocytosis is the main pathway for the uptake of 
macromolecules and particles from the surrounding medium[52]. The process 
involves endosome and lysosome internalization, where the pH can be as low as 
5.5-6.0 in the endosome and 4.5-5.0 in lysosomes[12, 125]. Therefore, drug 
carriers responsive to pH can be designed to selectively release their payload in 
tumor tissue cells for lysosomotropic delivery (Figure 4.1). Several different 
approaches have been reported, such as covalently conjugating drug molecules to 
drug carriers through a proteolytically cleavable bond or a hydrolytically unstable 
bond [126-129]. Another approach is to incorporate amines or carboxylic acids 
into block copolymers to form pH-sensitive micelles whose formation is altered 







Trafficking via endosomal 
compartments to lysosomes 
pH dependent liberation of 
drug, which diffuses out of 
lysosomes to access the 
therapeutic target 
pH = ~5 
 pH = ~7.4 
Figure 4.1 Lysosomotropic delivery (Duncan, Nature Reviews Cancer (2006)) 
 
In this study, Doxorubicin (Dox) was used as the model anticancer drug. Dox can 
be used to treat breast, ovarian and bronchial cancers by inhibiting the synthesis of 
nucleic acids in cancer cells. However, Dox has a very narrow therapeutic index 
and its use is thus limited [124]. Encapsulation of Dox provides a way to reduce 
toxicity through selective targeting and controlled release. In this chapter, loading 
and release of Dox is studied by controlling the bonding strength of the drug 
molecules to the magnetic nanotubes. 
Kataoka et al. studied the pH effect on the partition of Dox in aqueous/chloroform 




At pH > 7, Dox partitioning into the chloroform phase is higher than 90%. When 
pH < 5.5, the partition into chloroform phase is about 10% (Figure 4.2). 
According to these data, the release of Dox can be adjusted by pH. Ideally, 
nanotubes loaded with Dox will not release the drug during circulation in the 
blood, where pH > 7. Once the nanotubes are taken up by the cancer cells, the 
drug will be released in an acidic environment. The pKa value of pyridine in water 
is 5.3 [133]. It will be protonated when pH is less than 5.3 and will be in neutral 
form when the pH is around 7. When the pH is less than 5.3, Dox will also be 
protonated. For pyridine modified nanotubes, there will be charge-charge 
interaction and Dox will tend to leave the nanotubes at acidic pH. When the pH > 
7, there will be a hydrophobic interactions between Dox and pyridine that assists 
in holding the drug in the nanotubes. 
 
 





4.2 Materials and methods 
4.2.1 Materials 
Doxorubicin (Dox) in the form of the hydrochloride salt was purchased from 
Sigma-Aldrich. Dox base was prepared by mixing Dox with three equivalent of 
triethylamine (TEA, Fisher Scientific) in dimethylsulfoxide (DMSO, Fisher 
Scientific). Chloroform was purchased from Fisher Scientific. Silane agents were 
obtained from Gelest, including n-octadecyltrimethoxysilane (95%, C18-silane), 

























Acetic acid (J.T. Baker, Philipsburg, NJ) and sodium acetate (ACS reagent) were 
obtained from Fisher Scientific. HEPES buffer solution (1M) was obtained from 
Invitrogen. Piranha solution was prepared by mixing concentrated sulfuric acid 
(H2SO4, Fisher Scientific) and hydrogen peroxide (H2O2, 30%, Fisher Scientific) 
with a volume ratio of 3:1. Deionized (DI) water was obtained by a Milli-Q A10 
system and used for all the experiments. Magnetic nanotubes (silica nanotubes 
loaded with magnetic nanoparticles) with length of 2 μm were used for the study 
on Dox release at different pHs. 
4.2.2 Modification of nanotubes  
The inside surfaces of the nanotubes were modified with pyridine-silane to adjust 
the bonding strength of Dox molecules to the nanotubes by varying pH. The 
hydrophobic silane C18-silane was used together with pyridine-silane in order to 
increase the loading capacity and further adjust the release profile. The nanotubes 
were modified with pyridine-silane and C18-silane with three different ratios: 1) 
100% C18-silane (100C18), 2) 75% C18-silane and 25% pyridine-silane (75C18), 
and 3) 50% C18-silane and 50% pyridine-silane (50C18). The final concentration 




AAO templates were immersed in the pyridine-silane and C18-silane mixture for 
20 min, washed with ethanol and water, and then baked in an oven at 120 oC.  
4.2.3 Optical images 
Cover slips were cleaned with Piranha solution and then modified with 
tetraethoxysilane (TEOS) to immobilize nanotubes. Specifically, the cover slips 
were immersed in 1:1:4 mixture of 1M HCl, TEOS and ethanol, sonicated for 5 
min, and then rinsed with ethanol. 20 μl of a nanotube solution is dropped on the 
TEOS coated cover slips and dry overnight at 25°C. To obtain the fluorescence 
images, the sample was located with a microscope in wide field mode, and then 
imaged with a color Charge-Coupled Device (CCD) camera. 
4.2.4 Release profiles 
The amount of the nanotubes was calculated based on the pore density of the 
template (1010 per cm2) and the template area. The Dox base solution was 
prepared in 100 μl DMSO solution with 3 equivalent of TEA at first, and then 
diluted with chloroform with the Dox concentration of 5 mg/ml. The solution was 
kept in the dark at 4 °C overnight to allow the neutralization of Dox. Nanotubes 
were then incubated in the solution overnight at 4°C to attain equilibrium. The 
nanotubes are then collected and dried at 60°C. To remove weakly bound drug 
molecules, the nanotubes were rinsed with 20 mM HEPES buffer (pH 7.2) 
solution, and then re-dispersed in 20 mM HEPES (pH 7.2) buffer solutions to 




were obtained in acetate buffer (pH 4.5). The concentration of Dox was measured 
by spectrofluorophotometer (RF-1501, Shimadzu) with an excitation wavelength 
of 490 nm and an emission wavelength of 560 nm.  
4.3 Results and discussion 
4.3.1 Optical images 
Optical images of nanotubes loaded with Dox are shown in Figure 4.3. The 































































Figure 4.3 Optical images of SNTs loaded with Dox. (a) SNTs modified with 
100% C18-silane, (b) SNTs modified with 75% C18-silane and 25% pyridine-




4.3.2 Release profiles 
To measure the concentration of Dox, calibration curves at pH 4.5 and 7.2 were 
obtained, as shown in Figures 4.4 and 4.5.  
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Figure 4.5 Fluorescence spectra for Dox and calibration curves in HEPES buffer 
at pH 7.2  
 
The effect of pH on the release profile of Dox from the drug loaded nanotubes 
was studied, as illustrated in Figure 4.6. The fluorescence intensity was corrected 
to be the intensity per 1010 nanotubes by dividing the measured fluorescence 




Dox decreased with time. It can be explained by the intensity decay of the Dox 
molecular itself in the buffer solutions, as shown by the control sample. The 
control sample was prepared by diluting Dox base solution with HEPES (20 mM) 


















































































Figure 4.6 Effect of pH on the release profile of Dox from nanotubes 




The amount of Dox loaded in the nanotubes (mL) was calculated by multiplication 
of the concentration of the stock solution (5 mg/ml) and the total volume of the 
nanotubes. The payload mass of Dox was calculated to be 0.38 μg per 1010 
nanotubes. The amount of Dox remained in the nanotubes after release in HEPES 
buffer (mremain = mL - mpH7.2) were shown in Figure 4.7. There is no significant 
difference among the modified nanotubes and bare nanotubes based on the F-test. 
It indicates that physical trapping played the main role in loading Dox molecules 
in the nanotubes. 
The release profiles of Dox in acetic buffer solutions were shown in Figure 4.8. 
The release percentage (%Release) is defined to be the released amount over the 
amount of Dox remained in the nanotubes after release in HEPES buffer solutions 











lease ,   Equation 4.1 
 
where mpH4.5 is the amount of Dox released in acetate buffer solutions. This value 
is determined by the fluorescence intensity compared to the standard curve 
obtained in pH 4.5 buffer solutions. MpH7.2 is the amount of Dox released in 
HEPES buffer solutions which is also determined by the fluorescence intensity. 





The release profiles at pH 4.5 showed that the modified nanotubes had a lower 
release rate than the bare nanotubes (Figure 4.9). This indicates that the 




















































































Modification 100 C18 75 C18 50 C18 bare 
Slope (min
-1
) 0.0880 0.0965 0.0874 0.1871 
 
Figure 4.9 Releasing rates of Dox from MNTs 
 
Considering the potential acidic pH effect on the stability of magnetic 
nanoparticles, TEM images of MNTs were taken before and after incubation in 
acetic buffer solution with pH of 4.5 for 55 h. As illustrated in Figure 4.10, MNTs 







Figure 4.10 TEM images of magnetic nanotubes (MNTs) loaded with Dox before 
release (a) and after incubation in acetic buffer solution (pH 4.5) for 55 h 
 
4.4 Conclusions 
In summary, magnetic nanotubes can be used as drug reservoirs. The barrier effect 
of magnetic nanoparticles in nanotubes plays the main role in drug loading. Dox 
molecules were stable in the nanotubes at pH 7.2. They can be released at acidic 
pH. The modification of the inner surfaces of the nanotubes is effective in 




Chapter 5: Cellular Uptake and Cytotoxicity 
This chapter has been reproduced in part with permission from Nan, A; Bai, X; 
Son, SJ; Lee, SB; Ghandehari, H, Cellular uptake and cytotoxicity of silica 
nanotubes, Nano Lett., 2008, 8 (8): 2150-2154. 
5.1 Introduction 
Multifunctional nanocarriers used to date such as liposomes, linear polymers, 
nanoparticles, and dendrimers suffer from inherent limitations such as instability 
or polydispersity, and often result in nonspecific accumulation and toxicity in 
normal organs [134]. Several studies have suggested that physicochemical 
properties of nanocarriers such as size, shape and surface functionalization 
influence their biodistribution (i.e. passing through endothelial and epithelial 
barriers), targetability (either passively by size control or actively by attaching 
targeting moieties to the surface of the carrier), and bioactive agent release (by 
control of pore size within the carrier)[52]. Development of advanced delivery 
systems in which size, functionalization and loading capacity is precisely tuned 
may allow a higher degree of control over their biological fate. Such control could 
potentially enhance therapeutic efficacy and reduce non-specific toxicity 
associated with conventional carriers. 
Silica nanotubes (SNTs) prepared with the template synthesis method provide 
unique features such as monodispersity, distinctive inner and outer surfaces that 
can be differentially functionalized for loading biomolecules and targeting and 
biocompatibility, respectively. Magnetic nanotubes (MNTs), that is, silica 




magnetically controlled bioseparation and biointeraction [44] and as MRI contrast 
agents [135]. Combining the attractive tubular structure with superpaprmagnetic 
properties, SNTs can be an ideal multifunctional platform for magnetic resonance 
imaging (MRI) monitored delivery. SNTs are mechanically robust with no 
swelling or porosity changes under physiological conditions[136].  
Despite the unique advantages of SNTs in biomedical applications, exploration of 
their interactions with biological systems remains at a very early stage. 
Endocytosis has been demonstrated to be the main mechanism for cellular uptake 
of nanoparticles complexed with biological macromolecules, such as liposome-
oligodeoxynucleotides and polymer-DNA. However, the mechanism of the 
cellular uptake of carbon nanotubes (CNT) is not conclusive. CNTs have been 
demonstrated as an effective carrier for gene and anti-cancer drug delivery [27, 
70]. One of the key advantages of CNTs over other nanoparticles carriers has been 
considered to be the possibility of effectively crossing biological barriers [71]. 
Dennis Dishcer and colleagues have reported that filamentous polymeric micelles 
known as filomicelles (22 to 60 nm in diameter, and 2 to 8 um in length) have ten 
times longer blood circulation time than their spherical counterparts and have a 
high efficiency in delivering anticancer drugs [72]. However, the study of cellular 
uptake of gold nanoparticles (NPs) of different shapes showed a lower uptake of 
rod-shaped gold NPs in comparison to spherical shaped NPs and the rates of 




To effectively develop these systems for applications, it is necessary to study the 
structural and functional properties that influence biocompatibility and 
mechanisms of cellular uptake and interactions. In this chapter, the cytotoxicity 
and cellular uptake of SNTs with two different sizes and surface charges in 
primary (non-malignant) and cancer cell models were described.  
5.2 Experimental 
The template and SNT dimensions were characterized by field emission scanning 
electron microscopy (SEM, Hitachi S-4700) and ZEISS EM10CA transmission 
electron microscopy (TEM).  
5.2.1 Surface functionalizations 
The inner or outer surface of silica nanotubes was modified using commercially 
available silane reagents (Gelest, Morrisville, PA). For uptake studies nanotubes 
were modified in the inner surface to permit attachment of a fluorescent probe 
Alexa Fluor488 (Invitrogen, Eugene, Oregon). For this purpose nanotubes 
embedded in the alumina template were first modified with 3-
trimethoxysilylpropyl diethylenetriamine (95%, DETA). DETA was used as a 
linker to covalently bind Alexa Fluor to the inner surface of nanotubes. After 
dissolution of the template, liberated nanotubes were immersed in 1% Alexa Fluor 
488 TFP with 0.1 M sodium carbonate buffer solution for labeling. Stopping 




Scientific) was used to remove non-bound or weakly bound dye molecules. 
Nanotubes were washed and collected by filtration. 
Without any outer surface modification nanotubes are negatively charged under 
physiological conditions. To prepare positively charged outer surfaces, the 
nanotubes were treated with 5% aminopropyltrimethoxysilane (95%, APTS) in 















Figure 5.1 Schematic representation of template synthesis of silica nanotubes 
 
5.2.2 Growth inhibition assay of silica nanotubes 
Cytotoxicity of the SNTs was assessed on an epithelial breast cancer cell line, 
MDA-MB-231, and a Human Umbilical Vein Endothelial Cell (HUVEC) line by 
the standard MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, 
a tetrazole) assay. Briefly, cells were plated in 96 well plates (Corning, Inc., 
Corning, NY) at a density of 1000 cells/well. After 24h plates were incubated with 




of MTT solution for 1 h. Upon removal of the MTT solution, the purple formazan 
crystals produced were solubilized with 100 µl of DMSO and measured at 560 nm 
on a microplate reader (SPECTRAmax plus, Molecular Devices, Sunnyvale, CA). 
Toxicity was expressed as % of viable cells. Statistical significance of differences 
in toxicity between different samples was analyzed using a two-tailed unpaired 
student t-test. 
5.2.3 Confocal microscopy 
The localization of fluorescently labeled SNTs (labeled with Alexa Fluor 488) in 
the cellular and intracellular spaces was visualized via confocal laser scanning 
microscopy (CLSM). Images were obtained using a Nikon Eclipse TE2000 
inverted confocal microscope (Nikon Instruments, Inc., Melville, NY). Cells were 
seeded at a density of 30,000 cells/cm2 onto collagen-coated 4-chamber culture 
slides (BD Biosciences, Bedford, MA) and maintained under normal incubation 
conditions for 24h. The growth medium was replaced with PBS, and cells were 
equilibrated for 30 min before uptake experiments. Cells were treated with 300 μl 
of 0.01 μg/ml SNTs for 30 min. The nanotubes were removed by washing the 
cells 3 times with PBS. For colocalization studies, cells were subsequently chased 
with 300 µl pre-warmed (37°C) solution of various markers (Clathrin, Lysotracker 
Red) at 37°C for additional 30 min to allow internalization. The cells were then 
fixed with 300 μl of 4% paraformaldehyde for 20 min at room temperature. 
Nuclei of cells were stained with 300 μl of DAPI and incubated at room 




removed. Gel/Mount was added to each region and slides were covered with a 
glass coverslip, sealed, and dried overnight at 4°C. Images were obtained using a 
Nikon Eclipse TE2000 inverted confocal laser scanning microscope (Nikon 
Instruments, Inc., Melville, NY), equipped with an argon ion laser. DAPI was 
visualized with excitation and emission wavelengths of 405 nm and 450 nm, 
respectively; Alexa Fluor 488 was visualized with excitation and emission 
wavelengths of 488 nm and 515 nm, respectively. The 3-D confocal images were 
acquired using the following parameters of the Nikon EZ-C1 acquisition software 
(version 2.3, Image systems, Inc., Columbia, MD): 60x oil objective with 
numerical aperture = 1.4; 100 μm pinhole size; 9.64 μs scan dwell; 512 x 512 
pixel size; 0.5 μm z-step size. All images were recorded using an Image Quant Z-
stack which produced a three dimensional image of the samples. 
To investigate endocytic uptake, nanotubes were incubated at 37 °C  in the 
presence of 0.1% sodium azide [137] and hyperosmotic 0.45M sucrose [138] for 
10 min followed by treatment with SNTs. 
5.2.4 Transmission electron microscopy 
Following 30 min incubation with SNTs, the cells were fixed with 2.0% 
glutaraldehyde buffered in 0.1 M PBS for 1 hour at room temperature. After 
washing with 0.1 M PBS, the cells were collected in centrifuge tubes, and then 
post-fixed in 1% osmium tetroxide and 2% uranyl acetate. The samples were 
dehydrated through a series of alcohol concentrations (35%, 50%, 75%, 95% and 




Spurr’s resin by infiltration with a series of mixtures of resin and propylene oxide 
at ratios of propylene oxide to resin: 1:1, 1:2, 1:3 respectively. The sample was 
subsequently incubated at 70°C overnight. Ultra-thin sections with thickness about 
60 nm were obtained with ultrathin microtome (Reichert Ultracut, Vienna, Austria) 
and stained with 2.5% uranyl acetate and 2.5% lead citrate for transmission 
electron microscopy contrast enhancement. Cell and nanoparticle images were 
taken with ZEISS EM10CA TEM microscope (Thornwood, NY) operating at 80 
kV. All the chemicals for the preparation of TEM cell samples were obtained from 
Electron Microscope Science. 
5.2.5 Cell labeling with MNT-Pro complexes and assessment of toxicity 
Protamine sulfate (Pro) was used as a transfection agent [139]. Considering the 
potential interaction between Pro and serum, MNT-Pro was prepared in serum-
free RPMI 1640 media (Biosource, Camarillo, CA) with MNTs of 10 μg/ml and 
Pro of 40 μg/ml. The zeta potentials of 500 nm-MNTs and MNT-Pro complexes 
in PBS were measured with a Zeta Potential analyzer (Brookhaven Instrument, 
New York). A total of 10 runs were collected, and results are reported as mean 
and standard deviation. Rat glioma C-6 cells (ATCC Manassas, VA) were 
incubated in a 96-well plate. The media in the wells were then replaced with 500 
μl of serum-free media with MNT-Pro complexes. 500 μl of complete media was 
added in the well after 2 hrs. The cells were then incubated at 37 °C with 5% CO2, 
95% air for 24 hrs. The Prussian blue method was used to evaluate the labeling 




with the ferrocyanide and results in the formation of a bright blue pigment called 
Prussian blue, or ferric ferrocyanide [140]. The cells were washed three times with 
phosphoric buffer saline to remove unlabeled MNT-Pro complexes, trypsinized 
and transferred to cytospin slides. After drying overnight, the slides were 
incubated for 20 minutes in a mixture of 50 ml of 20% potassium ferrocyanide 
and 50 ml of 20% hydrochloric acid, washed, and then counterstained with 
nuclear fast red. This protocol has been published previously [93]. 
For the assessment of the MNT-Pro complexes toxicity, rat glioma C-6 cells 
grown in RPMI 1640 media were used. The glioma C-6 cells labeled with MNT-
Pro were evaluated with MTS (3-(4,5-dimethylthiazol-2-yl) -5-(3-
carboxymethoxyphenyl) -2- (4-sulfophenyl)-2H-tetrazolium) assay after one day 
incubation at 37˚C with 5% CO2, 95% air. The absorbance of the formazan 
product was then measured at a wavelength of 570 nm, with 750 nm as the 
subtracted reference wavelength. The results of the MTS assays were expressed as 
the percentage of the corresponding control cells. 
5.3 Results and discussions 
Using the “template synthesis” strategy (Figure 5.1) combined with surface sol-
gel chemistry, a series of 50 nm diameter SNTs was fabricated namely: 1) 200 and 
500 nm long, bare (non-functionalized) SNTs and 2) 200 and 500 nm long, SNTs 
functionalized with positively charged aminosilane group on the outer surface. 
The TEM images demonstrate discrete monodisperse dimensions (diameter and 




d). The dimensions of the nanotubes can be controlled by the pore diameter and 





Figure 5.2 Scanning electron microscope images of porous alumina template for 
SNT (diameter: 50 nm, length: 200 nm) (a) Top view, (b) Cross section, and 
Transmission Electron Microscope images of bare silica nanotubes (50 nm dia.) 
Length: (c) 200 nm, (d) 500 nm, with inset of TEM image for the cross section of 
the SNTs bundle. 
 
The effect of varying size and surface functionalization of SNTs on cytotoxicity 
was evaluated against two different human cell models: an epithelial breast cancer 
cell line (MDA-MB-231) and a primary umbilical vein endothelial cell line 




cellular environments that SNTs are likely to interact with in vivo. Results are 
reported as mean ± SEM (n=3). Statistically significant differences are indicated 
relative to 200 nm positively charged SNTs (*: p<0.002; **: p<0.02). In both the 
cell lines the SNTs exhibited growth inhibition in a concentration dependent 
manner. At lower concentrations (0.05 and 0.005 µg/ml) the nanotubes did not 
inhibit the growth of either of the above cell lines. At higher concentrations (5.0 
and 0.5 µg/ml) both the 200 nm and 500 nm SNTs caused up to 63% growth 
inhibition of breast cancer cells. At 5 µg/ml concentration, 200 nm positively 
charged SNTs were significantly more toxic (p<0.002) than the corresponding 
bare nanotubes (Figure 5.3a). This higher toxicity suggests the possibility of 
increased cellular association and/or uptake of the nanotubes due to non-specific 
interactions with the negatively charged cell surface. These observations are also 
in agreement with reports in the literature on other nanosized carrier molecules 
such as cationic polymers, amino or polylysine functionalized silica nanoparticles 
[141, 142], cationic dendrimers or several other positively charged nanostrucutres 
whose inherent cytotoxicity, and cellular uptake, is shown to be primarily 












Figure 5.3 MTT cytotoxicity assay showing the effect of varying concentrations o
nanotubes on growth inhibition of (a) MDA-MB-231 breast cancer cell
f 
s and (b) 
Human Umbilical Vein Endothelial Cells (HUVEC) cultured in vitro.  
Legends:  200 nm with positively charged APTS outer surface group;  200 nm 
with no outer surface functionalization;  500 nm with positively charged APTS 
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The nanotubes showed a similar trend for concentration dependent cytotoxic 
effects against the primary HUVEC cells (Figure 5.3b). However compared to 
breast cancer cells at high concentrations (5.0 and 0.5 µg/ml) the effect of size and 
charge seemed to be more significant. Positively charged nanotubes were 
significantly more toxic than bare nanotubes even at ten fold lower concentration 
(0.5 µg/ml) in HUVECs than in breast cancer cells. These results indicate that in 
addition to concentration and surface charge, cytotoxicity of SNTs is cell-type 
dependent. Reports in the literature on similar studies with silica nanoparticles 
suggest[143] that cancer cells are more resistant to nanoparticle mediated toxicity 
than normal non-malignant primary cells of the body. Some research groups 
attribute such resistance to the fact that normal primary cells of the body are more 
susceptible to nanoparticle mediated cellular membrane injury leading to more 
rapid onset of apoptotic or necrotic cell death[143-146]. Others more 
informatively relate cytotoxicity data of different cell lines to their metabolic 
activity or their rate of proliferation[143, 147]. The cell population doubling times 
of normal human endothelial cells were about 30 h compared to 20 h doubling 
time of the MDA-MB-231 breast cancer cells. However further mechanistic 
toxicity studies are needed to confirm these observations in the context of the 
SNTs. 
At higher concentrations (5.0 and 0.5 μg/ml) positively charged SNTs of smaller 
length (200 nm) were significantly more toxic to the HUVECs than their longer 




cancer cells. The results indicate that in addition to charge, size of nanotubes may 
also determine the extent of interaction with cells and toxicity. Reports in the 
literature[148-150] generally suggest that smaller sized particles allow increased 
cellular interactions and therefore may possess enhanced intrinsic toxicity. The 
cellular uptake can be considered as a result of competition between 
thermodynamic driving force for wrapping and the receptor diffusion kinetics[69]. 
Further, when comparing equivalent concentrations, the number of 200 nm SNTs 
is about 2.5 times of that of 500 nm given that they have the same mass. Therefore, 
smaller particle size along with increased number of particles may be responsible 
for the increased toxicity observed with the 200 nm length SNTs. Given the 
control over nanotube dimensions and functionalization using the template 
synthetic strategy one can conceive the ability to predict the influence of discrete 
size and charge on cytotoxicity and uptake. 
Although growth inhibitory effects were observed for both bare and positively 
charged SNTs these effects were primarily seen at very high concentrations. At 
0.05 µg/ml concentration (~ 108 SNTs/ml) and lower all SNTs irrespective of their 
surface characteristics were non-toxic. This indicates the suitability of these 
nanotubes for drug delivery applications. Additionally appropriate surface 
modification of SNTs such as with biocompatible polymers could potentially 
enhance their safety profile but such studies need to be performed. 
The internalization of SNTs was further evaluated by Transmission Electron 




vertically embedded (in the cross sectional view, marked by blue arrows) as 
confirmed by measurement of their diameters. Few intact nanotubes are seen in a 
horizontal alignment (lengthwise view Figure 5.4a marked with a red arrow). 





Figure 5.4 Transmission Electron Microscope images showing uptake of 500 nm 
positively charged SNTs in MDA-MB-231 cells. Blue arrows indicate cross 
sectional view and red arrows horizontal view of nanotubes. 
 
Finally, the possible mechanisms of cellular uptake of SNTs were evaluated. 
Reports in the literature suggest that the uptake of nanoparticulate systems into 
cells typically can occur through several different processes such as non-specific 
diffusion, phagocytosis and receptor mediated or fluid phase endocytosis [151]. 
As an initial attempt toward systematically delineating the mechanisms of uptake 
we investigated the involvement of fluid phase endocytosis. Confocal microscopy 




inhibitors. Results demonstrated cellular uptake of fluorescently labeled SNTs 
(200nm) (Figure 5.5a). Internalization of SNTs was significantly inhibited in 
presence of sodium azide (Figure 5.5b) and sucrose (Figure 5.5c) suggesting the 
involvement of fluid phase endocytosis. 
Endocytic uptake of the SNTs was further evaluated by colocalization with 
Clathrin (a marker of clathrin mediated early endosomal pathway) and 
Lysotracker (a marker for lysosomal uptake). Positively charged SNTs (labeled 
green) demonstrated a higher degree of association with the cell membrane as 
observed for both Clathrin (labeled red) and Lysotracker (labeled red) 
coincubation studies (Figure 5.6 b and d) than the respective studies with bare 
SNTs (Figure 5.6 a and c). This could be attributed to non-specific charge 
interaction of cationic SNTs with the negatively charged cell surface. SNTs 
colocalized (labeled orange) to a larger extent with the Lysotracker than with 
Clathrin suggesting that by 30 min most of the internalized nanotubes accumulate 
in the lysosomal compartment. Together these results qualitatively indicate that 
positively charged SNTs interact with cells and accumulate intracellularly to a 
greater extent than unmodified bare SNTs. Such increased interaction and uptake 
of positively charged SNTs could therefore be attributed to the increased toxicity 











Figure 5.5 Confocal microscope images of uptake of 200 nm positively charged 
fluorescent SNTs by MDA-MB231cells at 37°C. (a) without metabolic inhibitors, 
and in the presence of metabolic inhibitors of endocytosis namely (b) sodium 











 Figure 5.6 Confocal microscope images of uptake of fluorescent SNTs by MDA-
MB231cells. Colocalization studies with 200 nm SNTs with negatively (a and c) 
and positively charged (b and d) outer surfaces.  
(a) and (b) show colocalization of SNTs (green) with an early endosomal marker 
(Clathrin, red). (c) and (d) show colocalization with a lysosomal marker 
(Lysotracker, red). Nuclei of cell stained with DAPI (blue). Concentration of 







No significant toxicity was shown for the 500 nm-MNT labeled rat glioma cells 
with the MNT concentration up to 20 μg/ml for 24 hrs after labeling (Figure 5.7). 
The zeta potential for the MNT-Pro complexes for cell labeling is 12.39 ± 0.02 
mV while the zeta potential for bare MNTs is -25.68 ± 0.02 mV. The change in 
zeta potential of MNT following the addition of protamine sulfate would indicate 
that complexes form through van der Waals or electrostatic interactions. Cells 
were considered Prussian blue positive when intracytoplasmic blue granules were 
detected. The histology images show that more than 80% of the cells were labeled 
with 500 nm-MNTs successfully (Figure 5.8). However, the cells were not labeled 
heavily. Further studies are needed to optimize the labeling conditions to increase 
cellular uptake, such as tailoring the dimension of MNTs and preparing MNT-Pro 

























Figure 5.7 MTS cytotoxicity assay results for 500 nm-MNT labeled rat glioma 







Figure 5.8 Representative Prussian blue-stained (a) unlabeled cells and (b) MNT-
Pro labeled cells. 
 
5.4 Conclusions 
In summary, SNTs of discrete length, diameter and surface charge were fabricated. 
The nanotubes showed limited toxicity which was concentration- surface charge- 
and length- dependent and were internalized in cells at least in part by endocytosis. 
These initial studies pave the way for understanding the structural features of 
silica nanotubes influencing their behavior in cellular and tissue environments. In 
the long term these understandings can aid in designing silica nanotubes with 
specific biomedical applications including drug delivery. The preliminary studies 
on the in vitro cell labeling with MNTs reveal that the MNTs are not toxic, and 
the labeling is effective. These results indicate that this unique nanostructure 




Chapter 6: Segmented Modification of Nanotubes 
6.1 Introduction 
The increasing interest in medical applications of nanotechnology has heightened 
the need for synthesizing nanoparticles with well-defined dimensions and 
multifunctionalities. Template synthesis has become an important approach 
applied to nanomaterials synthesis [152-156]. It allows for the reproduction of the 
nano-structure with the best possible reproducibility. Anodic aluminum oxide 
films are popular due to their easy fabrication and control of pore dimensions by 
applying appropriate electrochemical parameters and chemical pore widening 
conditions[90, 157-160].  
6.1.1 Differential modifications 
With the template synthesis method, nanotubes with one open end are of 
particular interest for drug/gene delivery applications[48, 83, 161, 162]. Hollow 
tubular structures obtained can be differentially functionalized between the inner 
and outer surfaces, which provides a platform for multifunctionality through 
sequential surface modifications. Furthermore, the open ends of pores can serve as 
gates to control the release of drugs/genes while the inner voids can be loaded 
with a large amount of drugs [44, 49, 84]. Researchers have been exploring 
strategies for controlled payload-release. The idea is to design a universal delivery 
vehicle, capable of carrying a large payload, and has a cap which can be released 




It has been reported that controlled release of drugs from the tubular structure can 
be realized by capping the open ends of the tubular nanostructures with 
nanoparticles via chemically labile bonds[163-167]. Figure 6.1 shows 
schematically a controlled release mechanism. The system is based on the 
chemical reduction of a disulfide linkage between a CdS nanosphere cap and a 
mesoporous silica nanoparticle host. The drug release profile demonstrates that 
this strategy works under the experimental conditions[168]. However, there is a 
drawback for this system. The modification of the inner voids for pore caps can 
limit the types of drugs and/or the loading capacity. It is challenging to realize a 
drug-friendly inner void and chemically labile bonds for capping on the same 
nanotubular structure.  
Segmented modifications, that is, modifications of the entrance and the remainder 
of the tubular structure differently, can provide a way to solve this problem. The 
surfaces at the entrance of the nanotube can be used to link and release the cap 
while the chemistry for the rest inner surfaces of the nanotube can be drug-





Figure 6.1 Schematic representation of the CdS nanoparticles-capped mesoporous 





6.1.2 Segmented functionalizations 
In this chapter, the entrance of the silica nanotubes is modified differently from 
the remainder of the nanotubes. Photoresist is used as a mask for differential 
modification of the inner surface along the nanotubes, as shown in Scheme 6.1. 
Briefly, the pores of a silica-coated alumina template are filled with photoresist by 
spin-coating. With O2 plasma etching, the photoresist at the entrance of the pore 
structure is etched off. The exposed surface of the pores can then be modified with 
molecule A. The remainder can be modified with molecule B after the photoresist 
is removed. In this way, the modification at the entrance of the pore can be 
different from the rest of the pore. 
 















6.1.3 Dry etching 
The etching process involves transport of reactants to the surface of a substrate, 
surface reaction and transport of products from the surface. The advantage of dry 
etching over wet etching is its ability in defining small features since the reaction 
occurs in the gas phase. Dry etching technology can be classified into three types 
based on the etching mechanisms: physical sputtering, plasma etching and 
reactive ion etching. The etching mechanism changes with the ion energy which 
decreases with the pressure, as shown in Figure 6.2[169]. Physical sputtering 
requires the highest ion energy among these three. It relies on ion bombardment to 
remove the targeted materials. Plasma etching is achieved through plasma assisted 
chemical reactions. It requires the lowest ion energy among these three. The ions 
constantly bombard the surface and create damage in the form of unsatisfied 
bonds that are exposed to the reactive radicals. The radicals diffuse to the surface, 
quickly react to form volatile products, and are pumped away. Reactive ion 
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with the pressure [169] 
 
Plasma processing has gained wide use in materials processing because similar 
and more successful results cannot be attained using wet chemical etching. 
However, as the feature size decreases, the control of microscopic uniformity in 
high aspect ratio etching is becoming more and more challenging. It has been 
widely reported that smaller diameter holes and narrower trenches etch more 
slowly than larger diameter holes and wider trenches when the dimensions are 
below 1 μm. Many models have been built to qualitatively understand the 
dependence of etching rates on feature size. However, due to the complexity of 
the etching environment including the etch process parameters (pressure, rf power, 
etching gas chemistry, temperature) and the physical and chemical process 
parameters (energy and angular distribution of ions and neutrals, radical sticking, 
and surface charging), it is hard to make accurate profile predictions. Gottscho and 




etching rates into two categories: (1) aspect ratio dependent etching (ARDE), and 
(2) microloading [171]. ARDE is related with the transport of ions and neutrals in 
a microstructure. Typically, there is a substantial difference in mobility between 
lectrons and ions. The electrons have a large angular distribution while the ion 
72]. This difference leading to localized surface charging 
become  increased aspect ratio. Since the etching rate depends on 
the angular and energy distribution of the ions and neutrals flux, these factors will 
influence the etching profile. Microloading is due to inefficient supply of reactants 
under conditions where the etching reaction is reactant transport-rate-limited. This 








minoethyl)-3-aminoisobutyldimethylmethoxysilane (95%, ADMM-silane). 
Amine-reactive fluorescent probes Alexa Fluor 488 carboxylic acid 2,3,5,6-
tetrafluorophenyl ester (Alexa Fluor 488), Alexa Fluo 555 carboxylic acid, 
succinimidyl ester (Alexa Fluo 555) and thiol-reactive probe Alexa Fluor 555 C2 
maleimide (Alexa Fluo 555 C2) were obtained from Invitrogen (Eugene, Oregon). 
Traut’s reagent (2-imiothiolane HCl, The o Scientific, IL, USA) was used to 
modify amine and introduce sulfhydryl functional groups. 
6.2.1 Materials  





















6.2.2 Modifications of the inner surfaces of silica nanotubes 
The inner surfaces of silica nanotubes were modified when the nanotubes were 
still embedded in the AAO template. Specifically, the silica coated AAO was first 
immers l-water at room temperature, rinsed with ethanol, 
The preparation of anodic aluminum oxide (AAO) templates and the synthesis of 
silica nanotubes (SNTs) were introduced in Chapter 2. The SNT morphology was 
characterized by field emission scanning electron microscopy (SEM, Hitachi S-
4700) and ZEISS EM10CA transmission electron microscopy (TEM) operating at 
80 kV. 
ed in silane in 95% ethano
and then cured at 120 °C for 20 min. For DETA, the silane concentration was 5% 
and the immersion time was 30 min. For ADMM, due to its lower reactivity than 
DETA, the concentration used was 10% and the immersion time was increased to 





6.2.3 Photoresist coating 
After silane modification, the silica coated AAO was rinsed with acetone, 
isopropanol, and baked at 120 °C for 10 min. A drop of photoresist, Shipley 1813, 
was spread on the top of the AAO for 2 min. Spin-coating was carried out at 6,000 
RPM for 40 seconds. The sample was then soft-baked at 95 °C for 1 min and 
hard-baked at 120 °C for 5 min.  
6.3.4 O2 plasma etching 
o study the etching rate, silica coated AAO template was used. After spin 
e 
T
coating with photoresist, the sample was placed in a plasma chamber (Technics 
Model PE-IIA), as schematically shown in Figure 6.3. The chamber pressure was 
pumped down to 50 to 60 mTorr. Oxygen gas was then flushed in until the 
pressure reached 300 mTorr. The power was set to 100 W. The etching tim
ranged from 1 min to 4 min. Free standing silica nanotubes were obtained after the 







ctionalization of nanotubes 
he methodology is outlined in Scheme 6.2. Two sets of experiment were carried 
d 1: The silica coated AAO was modified with ADMM, then spin-
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om the template by 
with am  
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Power 













coated with photoresist. After dry etching by O2 plasma
rinsed off with ethanol. The nanotubes were then freed fr
selectively dissolving the template with 25% phosphoric acid and were labeled 
ine-reactive fluorescence probes for optical imaging. Method 2: The
 AAO was modified with DETA, then spin-coated with photoresist. 
2 plasma, the sample was dipped in Traut’s reag
l in 0.1 M sodium bicarbonate solution) for 2 hrs for thiolation. After the 









fluorescence images of these nanotubes were taken with fluorescence microscopy 
(Zeiss, Axioskop 2 MAT).  
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6.3 Results and discussions 
Figure 6.4 shows the scanning microscopy images of silica coated AAO. The 
transmission microscopy images of the silica nanotubes with inner pore blocked 


















































Figure 6.5 Transmission electron microscope (TEM) images of silica nanotubes 
before photoresist loading (a), and after photoresist loading with O2 plasma 




As shown in Figure 6.5, the etching depth increased with O2 plasma etching time 
while the etching rate decreased with the etching time. The difference in etching 
rates can be attributed to the change in the aspect ratio. As the etching proceeds, 
the aspect ratio continually increases, and the etching rates decrease. This result 
can be explained by ARDE and/or microloading, as introduced in 6.1.3.  
Figure 6.6 shows optical images of segmented-modified nanotubes based on 
method 1. The AMMD-silane modified nanotubes were partially labeled with 
fluorescent dye molecules, which indicate the success of the segmented 
modifications. However, the methods did not seem to work for the DETA-silane 
modified nanotubes. This difference may be explained by the different structure of 
the modification layer generated on the inner surfaces of the nanotubes. For the 
AMMD-silane modified surface, a mono-layer with amine functional groups was 
produced. When the top layers of photoresist were removed, the side chain of the 
AMMD-silane, which was linked to the nanotubes at the entrance, was exposed 
and then cleaved with the oxygen plasma during dry etching. The modification 
layer that was covered with photoresist was protected and could further react with 
amine-active probes. This can lead to the segmented modification of the probes in 
the step thereafter. For the DETA-silane modified nanotubes, the fluorescence 
images indicate that the amine functional groups were not completely removed by 
the O2 plasma. This could be the result of the formation of protection layer leading 
to etching stop. The DETA-silane molecule has three ethoxy groups bound to Si 




form an oligomer before or during silane modification. This can lead to a 
formation of multi-layer deposition instead of a monolayer on the substrate. 
During the O2 plasma etching process, the organic chains in the top layers were 
consumed and formed a crosslinked siloxane network. Since the transport of the 
oxygen radicals is quite directional under the low pressure, the siloxane network 
might act as an effective protection layer and hinder further cleavage of the 
organic side chains underneath the layer. The conversion of the top layer of 
SiOCH and SiCH film into a hydrophilic SiO -like porous material with O2 2 
plasma has been observed [173-175].  
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Figure 6.6 Optical images of differentially modified nanotubes based on method 1 
with inner surfaces pre-modified with AMMD-silane (a and b), and nanotubes pre-






Figure 6.7 shows the fluorescence microscopic images of nanotubes modified 
with two probes. The results suggest that method 2 was effective for segmented 
modifications. However, the two color bands were not distinctive. The overlap of 
these two probes could be a result of nonspecific bonding. Additionally, it is 
possible that the reaction efficiency between the Traut’s agent and the amine 
groups remained at the entrance after dry etching was not 100%. There were still 
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Figure 6.7 Fluorescence images of segmentedly modified nanotubes based on 
method 2 with inner surfaces pre-modified with DETA-silane. (a) with green dye 
filter, (b) with red dye filter , and (c) overlap of (a) and (b) 
 
6.4 Conclusions 
Nanotubes with their unique physical structure have potential advantages over 
spherical particles in terms of multifunctionality. The differential modifications 
between the inner and outer surfaces have been developed, as introduced in 




was developed. The results demonstrate that the method was effective even 
though more experiments need to be done to optimize the process parameters. 
With this segmented modification, nanotubes can work as a more efficient 




Chapter 7 Conclusions and Future Work 
. 




In this thesis, I developed a method of synthesis of magnetic nanotubes (MNTs). The 
structure of MNTs integrates the unique characteristics of SNTs, such as facile 
chemistry, robust mechanical properties, biocompatibility, and well-controlled 
dimensions, with the superparamagnetic properties of SPIONs. The saturation 
magnetization of MNT is as high as 95 emu/gFe, as described in Chapter 2.  
In Chapter 3, I characterized MNTs as magnetic resonance contrast agents. The 
results demonstrated that MNTs enhanced proton magnetic resonance relaxation 
considerably, especially transverse relaxation. The transverse relaxivities r2 (*) of 
MNTs are even higher than the values for Feridex, a FDA approved MR contrast 
agent, indicating that MNTs could potentially act as an efficacious T2-weighted MRI 
contrast agents. 
I modified MNTs with pyridine-silane and C18-silane and used them as drug carriers 
to control the release profile of Dox (Chapter 5). The interaction between the inner 
surface modified layer of MNT and Dox varies with pH. The results showed that Dox 
molecules held in the MNTs were stable at pH 7.2, and released at pH 4.5. It indicates 




Additionally, the barrier effect of the magnetic nanoparticles in the nanotubes helped 
in holding the drug molecules.  
I completed in-vitro cell labeling with MNTs, as introduced in Chapter 4. The 
preliminary studies on the in vitro cell labeling with MNTs reveal that the MNTs are 
not toxic, and the labeling is effective. To study the effect of structural and functional 
properties of nanotubes on cellular uptake and interactions, I did experiments on 
cytotoxicity and cellular uptake of SNTs with two different sizes and surface charges 
in primary (non-malignant) and cancer cell models were described. The nanotubes 
showed limited toxicity which was concentration-, surface charge-, and length- 
dependent and were internalized in cells at least in part by endocytosis. 
In Chapter 6, I designed a scheme to modify the nanotubes segmentally between the 
entrance and the remainder of the nanotube. The idea is to design a universal delivery 
vehicle that can be filled with a payload and has a cap which can be released in the 
environment where the drug molecules are to be delivered. I did some proof-of-
concept experiments. The results showed that the scheme was workable. 
7.2 Future work 
In this work, silica nanotubes/magnetic nanotubes are shown to be a promising 
candidate for biomedical applications. All the work done so far is just a start. More 
work need to be done to optimize the experimental conditions for materials synthesis 
and modifications. To continue the study on drug controlled release, we need data on 
long-term release and cumulative drug release before in vivo experiment. For the 




parameters, such as the surface charging, dimensions, concentration of nanotubes for 
cell labeling and cellular uptake. For all the possible clinical applications, the in vivo 
capabilities and limitations of SNTs need to be explored. Data on biodistribution 
would be very interesting. The pharmacokinetic parameters of in vivo administered 
functionalized SNTs need to be characterized for various therapeutic and diagnostic 
applications. 
With silica nanotubes as the constitute material, we can develop multimode imaging 
contrast agents combining MR with optical detection. Together with biomolecular 
targeting capabilities, we can obtain efficacious drug delivery modalities. Finally, we 
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